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Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that 
incorporates both intracellular and extracellular signals and plays a crucial role in cell 
metabolism, growth, proliferation and autophagy. mTOR exists in two structurally and 
functionally different multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). In particular, overactive mTORC1 reported to be associated with 
various human diseases such as diabetes, neurodegeneration and cancers. 
Rapamycin and its analogs which are well known allosteric inhibitor of mTORC1, binds 
to the FK506-binding protein 12 (FKBP12) and interacts with the FKBP12-rapamycin 
binding (FRB) domain in mTORC1. Although rapamycin and its analogues have been 
developed for the use of anti-cancer agents, these agents have limitations that only 
partially inhibit mTORC1 activity and rapamycin alone is not sufficient to control the 
mTORC1 activity in many pathological conditions. Thus, small molecules targeting other 
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possible regulators can offer alternative strategy to overcome rapamycin resistance in 
anti-cancer agents. 
Leucyl-tRNA synthetase (LRS) has been reported to be a possible mediator of 
intracellular amino acids signaling to mTORC1. LRS is a member of the class І 
aminoacyl-tRNA synthetase (ARSs) family that catalyzes the ATP-dependent ligation of 
leucine to cognate tRNA in protein biosynthesis. Recent studies indicate that LRS may 
act as a leucine sensor for the mTORC1 pathway. Given that mTORC1 is associated with 
cell proliferation and tumorigenesis, the LRS-mediated mTORC1 pathway may offer an 
alternative strategy in anticancer therapy.  
We have developed one of the leucinol analogs, (S)-4-isobutyloxazolidine-2-one as a 
LRS-targeted mTORC1 inhibitors. This compound inhibited downstream 
phosphorylation of mTORC1 by blocking leucine-sensing ability of LRS, without 
affecting the catalytic activity of LRS. In addition, it exhibited cytotoxicity against 
rapamycin-resistant colon cancer cells, suggesting that LRS has the potential to serve as 
a novel therapeutic target.  
Next, we developed leucyladenylate sulfamate derivatives as LRS-targeted mTORC1 
inhibitors. We demonstrated that (S)-2-hydroxy-4-methylpentanoyl adenylate sulfamate 
selectively inhibited LRS-mediated mTORC1 activation and exerted specific cytotoxicity 
against colon cancer cells with a hyperactive mTORC1.  
Furthermore, we replaced the adenylate group with a N-(3,4-
dimethoxybenzyl)benzenesulfonamide or a N-(2-phenoxyethyl)benzenesulfonamide 
groups that can maintain specific binding, but has more favorable physicochemical 
iii 
 
properties such as reduced polarity and asymmetric centers. Among these simplified 
analogues, we discovered that the compound and its constrained analogue effectively 
inhibited S6K phosphorylation in a dose-dependent manner and exhibited cancer cell 
specific cytotoxicity against six different types of cancer cells. 
In our continuing efforts to expand our in-house library of simplified leucyladenylates 
analogues, we decided to design new scaffolds based on the gefitinib structure. We 
devised new series of simplified structures by introducing N-(3-chloro-4-fluorophenyl) 
quinazolin-4-amine instead of adenine group and various linker structures to replace 5-
O-sulfamoylribose. We demonstrated that compounds with sulfonamide, ethyl alcohol or 
ethyl amino linker in new series of simplified adenylate structure showed potent 
inhibition. Furthermore, these compounds showed general cytotoxicity against various 
types of cancer cell lines, suggesting that they have a potential as effective anticancer 
agent. 
 
Keywords: Leucyl-tRNA synthetase, mTORC1 Inhibitor, Leucinol, Anticancer 
agent 
Student number: 2012-21602 
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1. Mammalian target of rapamycin (mTOR) 
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that 
incorporates both intracellular and extracellular signals and plays a crucial role in cellular 
metabolism, growth, proliferation and autophagy. mTOR exists in two structurally and 
functionally different multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) which have different sensitivities to rapamycin as well as upstream 
inputs and downstream outputs. mTORC1 regulates protein synthesis by phosphorylating 
downstream two major substrates, S6 kinase 1 (S6K1) and the translational regulators 
eukaryotic translation initiation factor 4E (elF4E)-binding protein 1 (4E-BP1), whereas 
mTORC2 regulates cytoskeletal organization, cell survival and metabolism.1 Given that 
the signaling pathways involving S6K1 and 4E-BP1 have been linked to tumorigenesis 
in many tissues, 2-4 rapamycin and its analogues have been developed for the use of anti-
cancer agents.5,6 
mTORC1 is composed of six different protein subunits whereas mTORC2 is composed 
of seven protein components. They share the catalytic mTOR subunits, mammalian lethal 
with sec13 protein 8 (mLST8, also known as GβL), DEP domain containing mTOR-
interacting protein (DEPTOR) and the Tti1/Tel2 complex. In contrast, regulatory-
associated protein of mammalian target of rapamycin (Raptor) and proline rich Akt 
substrate 40 kDa (PRAS40) are specific to mTORC1, whereas rapamycin-insensitive 
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companion of mTOR (Rictor), mammalian stress-activated map kinase-interacting 
protein 1 and 2 (Protor 1/2) are specific to mTORC2.1 
 
 
Figure 1. mTOR signaling pathway.7 
 
2. mTORC1 inhibitors 
The most studied compounds are rapamycin and its derivatives that directly bind near the 
mTOR kinase domain by forming a complex with the FK506-binding protein 12 
(FKBP12); temsirolimus and everolimus have been approved by the FDA for the 
treatment of advanced renal cell carcinoma,5,6 and ridaforolimus showed a promising 
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outcome in a recent clinical trial for advanced soft tissue and bone sarcoma.8,9 
Unfortunately, the efficacy of these rapamycin analogues, also called rapalogs, for the 
treatment of various cancer patients has been generally disappointing, mainly because 
these agents are cytostatic and only partially inhibit mTORC1 activity.10,11 Although 
rapamycin is a highly specific allosteric inhibitor of mTORC1, the mTORC1 pathway 
involves multiple regulatory mechanisms and complex feedback loops that have not yet 
been fully understood, thus resulting in an incomplete inhibition of kinase activity. 
Therefore, small molecules targeting other possible regulators may offer an alternative 
strategy for the suppression of mTORC1 activity, and have the potential to overcome 
rapamycin-resistance in cancer treatment. 
 
 
Figure 2. Ribbon diagram of human FKBP12 in complex with rapamycin interacting with 
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Figure 3. Structure of rapamycin and its analogues. 
 
3. LRS as a leucine sensor 
mTORC1 activity is regulated by various environmental signals, such as the levels of 
nutrients, energy, and oxygen. Although the complete mechanism of how mTORC1 
senses these signals still remains a mystery, the proteinogenic amino acid leucine is 
considered to be the master controller in amino acid-dependent mTORC1 signaling.12,13 
More importantly, several recent studies have reported that leucyl-tRNA synthetase (LRS) 
may act as an intracellular leucine sensor by directly binding to RagD GTPase, one of the 
key mediators of the amino acid-dependent mTORC1 pathway.14,15 LRS is a member of 
the class I aminoacyl-tRNA synthetase (ARSs) family that catalyzes the ATP-dependent 
ligation of amino acids to cognate transfer RNA (tRNA) in protein biosynthesis. Because 
of their pivotal role in cell survival, ARSs have been effective targets for antibiotics to 
overcome bacterial resistance,16-19 and also have been studied as anti-cancer agents.20-22 
In addition to its traditional role, LRS appears to participate in mTORC1 activation by 
acting as a GTPase-activating protein (GAP) for Rag GTPase in a leucine-dependent 
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leucine analogues, such as leucinol, without affecting the leucine charging ability of LRS, 
suggesting that LRS-targeted inhibitors can suppress mTORC1 activity.14, 23, 24 
 
 
Figure 4. Amino acid signaling to mTORC1.7 
 
4. Strategic Approach 
It is known that LRS functions as an intracellular leucine sensor in the amino acid-
dependent mTORC1 pathway by its activity as a GTPase-activating protein (GAP) for 
RagD.14 It is found that LRS directly interacts with GTP bound form of RagD GTPase 
but not with RagA, RagB and RagC. LRS interacts with only RagB/RagD heterodimers 
and forms a molecular complex with RagD and Raptor in an amino acid-dependent 
manner. When leucine concentration increases in the cell, lysosomal LRS acts as a leucine 
sensor and binds to GTP bound form of RagD and facilitates the conversion to an active 
form, leading to the lysosomal localization and activation of mTORC1.  
- 6 - 
 
As a new strategic approach, we designed the novel LRS-targeted mTORC1 inhibitor that 
can directly binds to LRS to inhibit mTORC1 signaling pathway. As our inhibitor binds 
to LRS catalytic site, the conformational change of LRS will prevent binding of LRS with 
RagB/RagD heterodimers to inhibit mTORC1 activation. 
 
 
Figure 5. Mechanism of novel LRS-targeted mTORC1inhibitors. 
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II. Part 1. Discovery of (s)-Isobutyloxazolidin-2-one as a Novel 
LRS-targeted mTORC1 Inhibitors 
 
1. Design background & strategy 
To develop LRS-targeted mTORC1 inhibitors, we first designed and synthesized a series 
of leucinol analogues.25 It has been reported that leucinol, which can be synthesized from 
the reduction of the carboxylic acid group of leucine, can block the amino acid stimulation 
of TOR signaling.23 Based on the leucinol structure, we designed the leucinol analogues 




Figure 6. Leucinol and its analogues. 
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2. Result and Discussion 
2.1. Chemistry 
Leucinol 1 and compounds 2-12 were prepared by following the pathway described in 
Scheme 1. Compounds 2 and 6 were prepared by carbonylation or methylation from 
leucinol respectively, which was prepared from commercially available N-Cbz-leucine by 
3 steps. Compounds 3, 8, and 10 were synthesized from the mesylated product of N-Cbz-
leucinol; compound 3 was obtained via deprotection of the N-Cbz group, and compounds 
8 and 10 were prepared by displacing the mesylate with a nitrile group followed by 
reduction or reductive hydrolysis respectively. Displacement of the mesylate with sodium 
azide yielded an azido intermediate, which was then used to prepare compounds 4, 5, 7, 
and 9. Hydrogenation in the presence of 10% palladium afforded diamine compound 4, 
and carbonylation of compound 4 yielded a cyclic analog, compound 5; selective 
reduction of the azide produced the N-Cbz protected monoamine intermediate, and 
subsequent methanesulfonylation or acylation, followed by deprotection produced 
compound 7 and 9 respectively. To prepare compound 11, N-Cbz protected leucinol was 
oxidized to aldehyde by Dess-Martin periodinane, and subsequent condensation with 
hydroxylamine, followed by deprotection yielded compound 11. Compound 12 was 
prepared from N-Boc protected leucine by applying the same procedure carried out for 
compound 11. 
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Scheme 1. Synthesis of leucinol analogures 1-12. 
Reagents & conditions: (a) cat. conc. H2SO4, MeOH, reflux, 12 h, 99% for N-Cbz, 45% 
for N-Boc; (b) NaBH4, EtOH, 0 oC→r.t, 56% for N-Cbz, 55% for N-Boc; (c) Pd/C, H2, 
MeOH, r.t, overnight, 89%; (d) 1, 1’-carbonyldiimidazole, DMF, r.t, 12 h, 39%; (e) MsCl, 
TEA, MC, 0 oC→r.t, 2 h, 90%; (f) 10% Pd/C, H2, MeOH, r.t, 12 h, 89%; (g) NaN3, DMF, 
80 oC, 4 h, 78%; (h) 10% Pd/C, H2, MeOH, r.t, 12 h, 33%; (i) 1,1’-carbonyldiimidazole, 
MC, r.t, 12 h, 54%; (j) NaH, MeI, DMF, 0 oC→r.t, 12 h; (k) benzyl chloroformate, K2CO3, 
acetonitrile, 0 oC→r.t, 5 h, 65%; (l) 10% Pd/C, H2, 2M NH3 in MeOH, r.t, 12 h, 99%; (m) 
PPh3, cat. H2O, THF, r.t, 12 h, 83%; (n) MsCl, TEA, MC, r.t, 1 h, 89%; (o) 10% Pd/C, H2, 
2M NH3 in MeOH, r.t, 12 h, 79%; (p) acetic anhydride, 80 oC, 12 h, 99%; (q) 10% Pd/C, 
H2, 2M NH3 in MeOH, r.t, 12 h, 98%; (r) NaCN, 15-crown-5, DMF, 60 oC, 48 h, 73%; (s) 
10% Pd/C, H2, MeOH, r.t, 12 h, 70%; (t) 6N HCl, reflux, 12 h, 99%; (u) BH3·THF, THF, 
reflux, overnight, 15%; (v) Dess-Martin periodinane, MC, r.t, 2 h, 61% for N-Cbz, 80% 
for N-Boc; (w) hydroxylamine hydrochloride, Na2CO3, MeOH, r.t, 12 h, 66% for N-Cbz, 
67% for N-Boc; (x) 10% Pd/C, H2, MeOH, r.t, 12 h, 86%. 
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Compound 13 was synthesized from commercially available imidazole-2-
carboxaldehyde (Scheme 2); the aldehyde group was converted to a nitrile group which 
was then reacted with isopropyl magnesium chloride to produce an imidazole 
intermediate containing an isobutyl ketone group. The ketone group was completely 
reduced by using Ni-Al catalyst to generate compound 13. 
Leucinol analogs with a chiral a-methyl group were synthesized by following the pathway 
described in Scheme 3. N-Dibenzyl protected leucinol was oxidized to aldehyde for 
subsequent Grignard reaction, providing a racemic alcohol mixture of R- and S- isomers 
with a ratio of 9:1. Final debenzylation of purified enantiomers yielded compounds 14 
(R-isomer) and 15 (S-isomer). The stereochemistry of each compound was assigned based 
on the previous report.26  
 
 
Scheme 2. Synthesis of compound 13. 
Reagents & conditions: (a) i) hydroxylamine hydrochloride, pyridine, r.t, 2 h, ⅱ) acetic 
anhydride, 80 oC→r.t, 5 h, 80%; (b) isopropylmagnesium chloride, THF, 0 oC→r.t, 3 h, 
77%; (c) Ni-Al alloy, H2O, reflux, 48 h, 50%. 
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Scheme 3. Synthesis of compounds 14 and 15. 
Reagents & conditions: (a) benzyl bromide, K2CO3, aq. MeOH, 65 oC, 2 h, 41%; (b) 
oxalyl chloride, DMSO, TEA, MC, -78 oC, 2 h; (c) CH3MgI, ether, 0 oC→r.t, 3 h, 60% 
(R:S=9:1); (d) 10% Pd/C, H2, MeOH. r.t, overnight, 62% for 14, 47% for 15.  
 
2.2. Biological Activity 
As a primary screening, we first assessed the effect of each compound on leucine-induced 
phosphorylation of S6 Kinase (S6K) by immunoblotting. S6K is one of the mTORC1 
substrates, and pretreatment with leucinol appears to block phosphorylation of S6K by 
inhibiting LRS.16 We treated HEK293 cells with each compound at 1 mM concentration, 
along with rapamycin as a control at 100 nM; and then activated mTORC1 by treating 
cells with leucine for 10 min. As demonstrated in Figure 7, leucine treatment induces 
phosphorylation of S6K, whereas pretreatment with rapamycin or deprivation of leucine 
blocked the phosphorylation. Pretreatment of leucinol also inhibited the phosphorylation 
to some extent, while compounds, 2, 5, 11, and 13 appeared to inhibit the phosphorylation 
more effectively than leucinol at the same concentrations. It is interesting to note that all 
four compounds have multiple heteroatoms that can participate in additional hydrogen 
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bond interactions compared to leucinol. It is also noticeable that compounds 2, 5, and 13 
are all cyclic analogs. Introduction of an additional methylene group or chiral a-methyl 
group did not generate any desirable activity. Addition of a relatively bulky functional 
group such as methanesulfonyl, mesyl, and acetyl group at the alcohol position also do 
not produce inhibitory effects, suggesting that leucine binding site is highly specific and 
only afford a small sized residue. 
 
Figure 7. Inhibition of LRS-mediated mTORC1 activation of synthesized leucinol 
analogues on HEK293 cells.  
 
Based on the primary screening results, we decided to focus on compounds 2, 5, 11, and 
13, and further determined the inhibitory effects on leucine-induced mTORC1 activation 
at the various concentrations by immunoblotting. As shown in Figure 8, all four 
compounds inhibited S6K phosphorylation in a dose-dependent manner while their 
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apprent potency decreases in the order of 5 > 13 > 11 > 2. The cyclic analogs, compounds 
5 and 13 appear to be more potent than leucinol, however, another cyclic derivative 
compound 2 only differs from compound 5 by one atom, and yet exhibits significantly 
lower activity. Additionally, we examined the effect of each compound on mTORC2 
activation by using Akt as the marker.1 All tested compounds including rapamycin and 
leucinol do not affect the cellular levels of Akt or phosphorylated Akt (pAkt) indicating 
that biological effects of these compounds are indeed mTORC1 specific. 
 
Figure 8. Dose-dependent inhibition of LRS-mediated mTORC1 activation of selected 
leucinol derivatives on HEK293 cells. Rapamycin was treated at 100 nM, leucinol was at 
800 M, and compounds 2, 5, 11, and 13 were treated at 100, 200, 400, and 800 M. 
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To investigate the mechanisms of leucine analogs in LRS-mediated mTORC1 activation, 
we examined the effects of compounds 5 and 13 on the catalytic activity of LRS. More 
specifically, since LRS catalyzes leucylation in the presence of tRNA, we carried out 
leucylation assays on these compounds. As shown in Figure 9, both compounds 5 and 13 
are poor inhibitors of aminoleucylation, having IC50 values in the high millimolar range. 
Given that both compounds inhibited phosphorylation of S6K at micromolar 
concentrations, our result indicates that these leucine analogs do not affect catalytic 
activity of LRS, which is in agreement with the previously reported observation that LRS 
activates mTORC1 signaling via leucine recognition without involving tRNA charging.14  
 
Figure 9. Aminoacylation activity of compound 5 and 13.  
 
Since mTORC1 is found to be overactive in many cancers, we evaluated cytotoxicity of 
compound 5 in cancer cells. In particular, mTORC1 is reported to be hyperactive in 
human colorectal cancer,27 however, rapamycin appears to be mostly ineffective.28 We 
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selected a human colon cancer cell line (SW620) which is known to be rapamycin 
resistant,29 to see whether blocking LRS can solve the resistance issue. After treating cells 
with each compound, we performed cytotoxicity assays by using CellTox Green 
fluorescent dye which stains the DNA from dead cells (Figure 10). As we expected, 
rapamycin did not exhibit significant cytotoxicity while leucinol seemed to be marginally 
cytotoxic even at the high concentrations; however, compound 5 demonstrated a dose-
dependent cytotoxicity, exerting a much greater magnitude of cytotoxic effects at the 
same concentrations compared to leucinol. Considering that compound 5 was more potent 




Figure 10. Cytotoxicity of compounds 5 in rapamycin-resistant colon cancer cell 
(SW620). 
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3. Conclusion 
In summary, we have developed a series of leucinol analogs that can inhibit mTORC1 
signaling pathway by blocking leucine-sensing ability of LRS. These analogs act as a 
competitive inhibitor of leucine in LRS-mediated activation of mTORC1, thereby 
inhibiting downstream phopshoprylation of S6K. In vitro mTORC1 inhibition study 
showed that compound 5, which contains an imidazolidin-2-one side chain, effectively 
inhibited leucine-mediated mTORC1 activation; however compound 5 did not suppress 
mTORC2 activation, nor did it affect catalytic activity of LRS. Furthermore, compound 
5 exhibited much higher cytotoxicity than leucinol against rapamycin-resistant colon 
cancer cells, implying that effective inhibition of leucine-sensing in the mTORC1 
pathway may play an important role in conferring cytotoxicity. Taken together, we believe 
that the blockade of leucine-sensing ability of LRS in the mTORC1 pathway has the 
potential to serve as a novel therapeutic target. 
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III. Part 2-1. Discovery of Leucyladenylate Sulfamates as a 
Novel LRS-targeted mTORC1 Inhibitors 
 
1. Design background & strategy 
Previously, we have demonstrated that a leucine analog, (S)-4-isobutyloxazolidin-2-one, 
selectively inhibited downstream phosphorylation of mTORC1 by blocking the leucine-
sensing ability of LRS.25 Furthermore, this analog exhibited cytotoxicity against 
rapamycin-resistant colon cancer cells without affecting the catalytic activity of LRS, 
indicating that LRS has the potential to serve as a novel therapeutic target. In a continuing 
effort to develop LRS-targeted mTORC1 inhibitors, we designed a new series of 
compounds based on the structure of aminoacyl adenylate 1, an enzymatic reaction 
intermediate of ARSs.30 Aminoacyl adenylates have been extensively studied as a lead 
compound for ARS inhibitors.31,32 Specifically, replacing the hydrolytically unstable 
acylphosphate group with its isosteres, such as acylsulfamate, resulted in chemically 
stable and potent inhibitors with IC50 values in the submicromolar to low micromolar 
range versus the corresponding ARSs.33-35 Based on these previous findings, we 
synthesized a library of leucyladenylate sulfamates by modifying adenine, ribose and 
leucine moieties and evaluated their biological activity. Among the more than 70 
compounds that we studied, herein we describe three representative compounds shown in 
Figure 11. Each of these three compounds contains distinct structural features that are 
required for either LRS inhibition or LRS-mediated mTORC1 suppression. 




Figure 11. Amionacyl adenylate 1 and leucyladenylate sulfamates. 
 
2. Result and Discussion 
2.1. Chemistry 
Synthesis of leucyladenylate sulfamate 6 began with commercially available 2’,3’-
isopropylidene adenosine 3 as shown in Scheme 4. Compound 3 was reacted with 
sulfamoyl chloride prepared in a quantitative yield from chlorosulfonyl isocyanate 
according to previously described procedures.37 Sulfamoylated adenosine 4 was then 
coupled with N-Boc-leucine to give the leucine adduct 5, which was subsequently 
hydrolyzed to leucyladenylate sulfamate 6. 
Synthesis of a syn-diol analog of leucyladenylate sulfamate 12 was carried out as 
illustrated in Scheme 5. 5’-O-Monomethoxytritylation (MMT) of compound 7 followed 
by acetylation of adenosine provided the fully protected adenosine 8. Selective removal 
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of MMT group and subsequent sulfamoylation produced the sulfamate intermediate 10. 
(2S,3R)-dihydroxy-4-methylpentanoic acid (DMPA) protected by O-diacetyl was 
prepared from 4-methyl-2-pentenoic acid in 4 steps by Sharpless asymmetric 
dihydroxylation, and its configuration was confirmed by following previously described 
procedures.36 Amide coupling between compound 10 and the protected chiral acid 
produced compound 11, four acetyl groups of which were then removed in the presence 
of sodium methoxide to yield the final compound 12.  
 
 
Scheme 4. Synthesis of the Leucyladenylate Sulfamate 6.  
Reagents & conditions: (a) i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 
oC to r.t, 5 h; (b) N-Boc leucine, DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h; (c) 80% aq. TFA, 
r.t, 2 h. 
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Scheme 5. Synthesis of Diol analogue of leucyladenylate sulfamate 12. 
Reagents & conditions: (a) MMTCl, anhyd. pyridine, anhyd. DMF, 0 oC to r.t, 24 h; (b) 
acetic anhydride, TEA, DMAP, CH3CN, 0 oC to r.t, 4 h; (c) 80% aq. AcOH, r.t, 12 h; (d) 
i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 oC to r.t, 5 h; (e) chiral acid, 
DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h; (f) 0.02M NaOMe in MeOH, r.t, 2 h. 
 
 
Synthesis of a hydroxyl surrogate of leucyladenylate sulfamate 18 is shown in 
Scheme 6. 2-Iodoadenosine (14) was synthesized from guanosine (13) in 4 steps 
according to previously described procedures.37 Compound 14 was converted to the 
corresponding 5’-O-sulfamoylated intermediate 16 by following the route described in 
Scheme 5. (2S)-hydroxyisocaproic acid (HICA, L-leucic acid) protected by O-acetyl was 
prepared by acetylation of commercially available L-leucic acid. A peptide coupling 
reaction between compound 16 and O-acetyl-L-leucic acid followed by deprotection of 
the acetyl group provided the final compound 18. 
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Scheme 6. Synthesis of (S)-2-hydroxy-2-iodo-sufamoyl-adenosine 18.  
Reagents & conditions: (a) Ac2O, TEA, DMAP, CH3CN, 0 oC to r.t, overmight; (b) POCl3, 
Et4NCl, PhNMe2, CH3CN, r.t to reflux, 1 h; (c) isoamyl nitrite, I2, CuI, CH2I2, THF, reflux, 
1 h; (d) 7M NH3 in MeOH, r.t, overnight; (e-j) the same conditions as (a-f) in scheme 2. 
 
2.2. Biological Activity 
Because LRS catalyzes leucylation reaction with its cognate tRNA during protein 
synthesis, we first assessed the inhibitory effects of compounds 6, 12 and 18 on the 
catalytic activity of LRS by performing aminoleucylation assays to determine the IC50 
values. Given that the previously reported acylsulfamate adenylates were found to be 
potent inhibitors of the corresponding ARSs, these compounds would be likely to exhibit 
inhibitory effects of LRS. As shown in Figure 12, compound 6 proved to be a potent 
inhibitor of LRS with an IC50 value of 22.34 nM. However, compounds 12 and 18 
inhibited LRS to a much lesser extent, showing 3- and 15-fold higher IC50 values (70.04 
nM and 337.1 nM, respectively) than compound 6. Replacement of the α-amino group of 
leucine side chain with a hydroxyl group (12), and the introduction of a 2-iodo group to 
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adenine (18) weakened the overall binding affinity toward the LRS active site. Moreover, 
considering fold-changes between compounds, we conclude that modification of the 
adenine moiety has a higher impact on the catalytic activity than the modification of the 
leucyl side chain. 
 
 
Figure 12. Inhibitory activities of compounds 6, 12 and 18 for catalytic leucylation.  
 
Next, we determined the effects of compounds 6, 12, and 18 on leucine-induced 
mTORC1 activation using the immunoblotting method. In our previous study, 
pretreatment of leucinol analogs blocked leucine-induced phosphorylation of S6K, an 
mTORC1 substrate, by directly interacting with LRS24; because the newly designed 
compounds have additional adenosine moieties, we would expect to observe stronger 
inhibitory effects for S6K phosphorylation. We pretreated HEK293 cells with each 
compound at different concentrations as well as with rapamycin as a control at 100 nM, 
and then activated mTORC1 by treating the cells with leucine for 10 min. As shown in 
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Figure 13, pretreatment of rapamycin blocked phosphorylation of S6K, whereas 
pretreatment of compound 6 did not affect S6K phosphorylation at all (Figure 13A). 
Notably, compounds 12 and 18 showed a dose-dependent inhibition of mTORC1 in 
HEK293 cells (Figure 13B, 13C) while compound 18 appeared to be more potent than 
compound 12. Interestingly, these three sulfamates inhibited leucine-induced mTORC1 
activation in the order of 18 > 12 > 6, in contrast to the order of their inhibitory effects 
for the catalytic reaction (6 > 12 > 18). This apparently opposite trend suggests that LRS-
mediated mTORC1 activation is independent of the leucylation activity of LRS on its 
cognate tRNA, which is again in agreement with previously reported observations.13, 24 
More interestingly, the side chain modifications of an α-hydroxyl group in the leucyl side 
chain and a 2-iodo group in the adenine, both of which adversely affected the catalytic 
activity of LRS, resulted in favorable effects for the mTORC1 inhibition.  
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Figure 13. Dose-dependent inhibition of leucine-induced mTORC1 activation of c
ompounds 6, 12 and 18 in HEK293 cells 
 
To further investigate the mechanisms of these sulfamates in LRS-mediated 
mTORC1 activation, we performed in vitro mTORC1 kinase assays using purified mTOR. 
As demonstrated in Figure 14, compounds 12 and 18 both did not inhibit the kinase 
activity of the purified mTOR at 200 µM, suggesting that these compounds are highly 
selective toward LRS, and did not act as an ATP-competitive inhibitor of the mTOR 
complex. We believe that these two sulfamates, 12 and 18, inhibited the mTORC1 activity 
by selectively blocking the LRS-mediated mTORC1 activation pathway, rather than 
directly interacting with mTOR. 
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Figure 14. Effects of compounds 12 and 18 on the kinase activity of the purifie
d mTOR. 
 
Finally, to examine the anti-cancer activity of leucyladenylate sulfamates, we performed 
the sulforhodamine B (SRB) colorimetric assays for cytotoxicity.38 We treated 
compounds 6, 12, and 18 with six different types of cancer cell lines together with 
etoposide as a positive control. To determine cancer cell selectivity, we also treated all 
four compounds with normal human lung epithelial cells (MRC-5), with the measured 
IC50 values shown in Table 1. Compound 6, the most potent LRS inhibitor, exhibited the 
greatest cytotoxicity that was even greater than that of etoposide in all types of cells, 
except A549 and SNU638. Given that LRS plays a crucial role in protein synthesis, it is 
not surprising that compound 6 is highly cytotoxic in both cancer cells and normal cells. 
In contrast, compounds 12 and 18 showed selective cytotoxicity against cancer cells. 
Specifically, compound 18 showed potent cytotoxicity against colon cancer cells 
(HCT116) and leukemia cells (K562) while exhibiting much less cytotoxicity against 
normal cells compared with compound 6 and etoposide. This result is particularly 
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promising because several recent studies have reported that hyperactive mTORC1 is one 
of the distinctive features in human colorectal cancer.39,40 suggesting that compound 18 
exerted colon cancer specific cytotoxicity by selective inhibition of mTORC1. 
 
Table 1. Relative cell growth inhibition of compounds 6, 12 and 18 for various 
cancer cell types and normal cells.a 
IC
50
 (μM) A549 HCT116 K562 MDA-MB-231 SK-HEP-1 SNU638 MRC5
6 0.59 0.24 0.4 0.73 0.54 0.84 5.9 
12 1.64 1.44 2.22 7.01 6.81 8.98 >50 
18 1.75 0.54 1.06 12.6 5.63 5.7 >50 
Etoposide 0.24 1.25 1.79 7.35 0.25 0.56 12.7 
aA549: lung cancer cells, MDA-MB-231: breast cancer cells, SK-Hep-1: liver cancer cells, SNU638: 




We have developed leucyladenylate sulfamate derivatives that directly interact with LRS 
to inhibit the mTORC1 pathway. Compound 6 inhibited the catalytic activity of LRS but 
did not affect the leucine-induced mTORC1 activation, whereas compound 18 inhibited 
mTORC1 activation, while it also inhibited the catalytic activity of LRS to a much lesser 
degree compared to compounds 6 and 12. Furthermore, both compounds 12 and 18 did 
not affect the kinase activity of the purified mTOR, indicating that the mTORC1-specific 
activity of these compounds arose from blocking the leucine-sensing ability of LRS rather 
than from interacting with mTOR directly. Cytotoxicity screening in various types of 
cancer cells and normal cells revealed that compound 6 showed the greatest cytotoxicity, 
probably due to a non-specific inhibition of LRS. Compounds 12 and 18 demonstrated 
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cytotoxicity against all types of cancer cells but not against normal cells. Most notably, 
compound 18 exerted highly specific cytotoxicity against colon cancer cells that are 
known to have hyperactive mTORC1. We believe that compound 18 may serve as a useful 
tool to study the role of LRS in the mTORC1 pathway but may also offer a novel treatment 
option for human colorectal cancer. 
 
4. Experimental 
4.1. General Experimental 
All chemical reagents were commercially available. Melting points were determined on 
a Büchi Melting Point B-540 apparatus and are uncorrected. Silica gel column 
chromatography was performed on silica gel 60, 230-400 mesh, Merck. Nuclear magnetic 
resonance (1H-NMR and 13C-NMR) spectra were recorded on JEOL JNM-LA 300 [300 
MHz (1H), 75 MHz (13C)] and Bruker Avance 400 MHz FT-NMR [400 MHz (1H), 100 
MHz (13C)] spectrometers. Chemical shifts are reported in ppm units with Me4Si as a 
reference standard. Mass spectra were recorded on a VG Trio-2 GC-MS and 6460 Triple 
Quad LC/MS. All final compounds were purified to >95% purity, as determined by high-
performance liquid chromatography (HPLC). HPLC was performed on an Agilent 1120 
Compact LC (G4288A) instrument using an Agilent Eclipse Plus C18 column (4.6 x 250 
mm, 5 μm) and a Daicel Chiralcel OD-H column (4.6 x 250 mm, 5 μm). 
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4.2. Procedures and Chemical spectra 
4.2.1. ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetra-
hydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate (4).  
Compound 4 was prepared by following the reported procedure.32 Yield 69%, white solid; 
1H-NMR (300MHz, CD3OD) δ 8.27 (s, 1H, CH), 8.22 (s, 1H, CH), 6.24 (d, 1H, CH, J = 
2.55 Hz), 5.42 (dd, 1H, CH, J = 6.24 Hz, 2.58 Hz), 5.13 (dd, 1H, CH, J = 6.21 Hz, 2.73 
Hz), 4.51 (m, 1H, CH), 4.32 (dd, 1H, CH, J = 10.62 Hz, 4.59 Hz), 4.24 (dd, 1H, CH, J = 
10.62 Hz, 5.31 Hz), 1.60 (s, 3H, CH3), 1.39 (s, 3H, CH3) 
 
4.2.2. ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetra 
hydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ((tert-butoxy carbonyl)-L-leucyl)sulfamate 
(5).  
To a solution of compound 4 (0.54 mmol) in anhydrous MC (25 mL) was added N-Boc 
leucine (0.81 mmol) and DMAP (0.01 mmol) at 0oC. 1M DCC in MC (0.81 mmol) was 
added dropwise, stirred for 2 h at room temperature. The solution was filtered on celite 
pad, washed with EtOAc (20 mL), and then concentrated. The filtrate was purified by 
column chromatography over silica gel (EtOAc:MeOH=10:1) to give the compound 5 
(0.46 mmol). Yield 85%, white solid; 1H-NMR (300MHz, CD3OD) δ 8.47 (s, 1H, CH), 
8.21 (s, 1H, CH), 6.22 (d, 1H, CH, J = 3.30 Hz), 5.33 (dd, 1H, CH, J = 5.88 Hz, 3.48 Hz), 
5.10 (d, 1H, CH, J = 5.67 Hz), 4.53 (m, 1H, CH), 4.23 (d, 2H, CH2, J = 3.48 Hz), 4.06 
(m, 1H, CH), 1.69 (m, 1H, CH), 1.60 (s, 3H, CH3), 1.52 (m, 2H, CH2), 1.43 (s, 9H, CH3), 
1.40 (s, 3H, CH3), 0.93 (dd, 6H, CH3, J = 6.60 Hz, 2.76 Hz) 
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4.2.3. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetra hydrofuran-2-
yl)methyl (L-leucyl) sulfamate trifluoroacetate salt (6).  
The compound 5 (0.38 mmol) was dissolved in 80% aquous TFA (2mL) and stirred for 2 
h at room temperature. The reaction mixture was evaporated and washed with EtOAc (20 
mL). Aqueous layer was concentrated under reduced pressure to give crude pale yellow 
solid. The solid was purified by ion-exchange resin (HP20SS) to give the compound 6 
(0.16 mmol). Yield 42%, white solid; 1H-NMR (500MHz, CD3OD) δ 8.49 (s, 1H, CH), 
8.20 (s, 1H, CH), 6.07 (d, 1H, CH, J = 5.30 Hz), 4.62 (t, 1H, CH, J = 5.10 Hz), 4.39-4.29 
(m, 4H, , 2 CH, CH2), 3.61 (dd, 1H, CH, J = 8.50 Hz, 4.85 Hz), 1.78 (m, 2H, CH2), 1.57 
(m, 1H, CH), 0.95 (dd, 6H, CH3, J = 15.95 Hz, 6.00 Hz); HRMS-FAB m/z [M+H]+ 
C16H25N7O7SH+ calcd 460.1536, Found: 460.4898. 
 
4.2.4. (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-(((4-methoxyphenyl) 
diphenylmethoxy)methyl)tetrahydrofuran-3,4-diyl diacetate (8).  
5’-O-Monomethoxytrityl (MMT) protected adenosine (2.27 mmol) was prepared by 
following the reported procedure.38 To a solution of 5’-O-MMT protected adenosine (2.05 
mmol) in acetonitrile (50 mL) at 0oC was added DMAP (0.21 mmol), TEA (6.15 mmol) 
and acetic anhydride (6.15 mmol). The mixture was stirred for 4hr at room temperature. 
Aqueous portion was extracted with EtOAc (50 mL). The organic phase was dried over 
MgSO4 and concentrated, which was purified by column chromatography (EtOAc:MeOH 
= 40:1, v/v) to give compound 8 (1.6 mmol). Yield 78%, white solid; 1H-NMR (300MHz, 
CDCl3) δ 8.01 (S, 1H, CH), 7.90 (S, 1H, CH), 7.42 (m, 4H, Ar), 7.32 (m, 4H, Ar), 7.25 
(m, 4H, Ar), 6.18 (m, 4H, Ar), 6.26 (d, 1H, CH, J =  6.6 Hz), 6.07 (t, 1H, CH, J = 5.3 
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Hz), 5.67 (dd, 1H, CH, J = 5.1 Hz, 3.1 Hz), 4.31 (m, 1H, CH), 3.78 (S, 3H, CH3), 3.46 
(m, 1H, CH), 2.10 (S, 3H, CH3), 2.05 (s, 3H, CH3) 
 
4.2.5. (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl) 
tetrahydrofuran-3,4-diyl diacetate (9).  
80% aquous AcOH (100 mL) was slowly added to compound 8 (1.52 mmol) and the 
reaction mixture was stirred for 12 h at room temperature. The mixture was evaporated, 
neutralized with NaHCO3 and extrated with EtOAc (150 mL x 2). Organic layer was 
combined, dried over MgSO4 and evaporated. The residue was purified by column 
chromatography (EtOAc:MeOH = 20:1, v/v) to give compound 9 (0.97 mmol). Yield 64%, 
white solid; 1H-NMR (300MHz, CDCl3) δ 8.32 (s, 1H, CH), 7.85 (S, 1H, CH), 6.26 (S, 
2H, NH2), 6.03 (d, 2H, CH2, J = 2.0 Hz), 5.70 (m, 1H, CH), 4.37 (s, 1H, CH), 3.99 (dd, 




methyl)tetrahydrofuran-3,4-diyl diacetate (10).  
Compound 10 was prepared by following the procedure described for compound 4. Yield 
93%, white solid; 1H-NMR (300MHz, CDCl3) δ 8.34 (s, 1H, CH), 8.00 (s, 1H, CH), 6.16 
(d, 1H, CH, J = 6.1 Hz), 5.91 (t, 1H, CH, J = 5.9 Hz), 5.72 (m, 1H, CH), 2.16 (s, 3H, 
CH3), 2.07 (s, 3H, CH3) 
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4.2.7. (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-(((N-((2S,3R)-2,3-diacetoxy-4-
methylpentanoyl)sulfamoyl)oxy)methyl)tetrahydrofuran-3,4-diyl diacetate (11).  
Compound 11 was prepared by following the procedure described for compound 5. Yield 
79%, white solid; 1H-NMR (300MHz, CD3OD) δ 8.47 (s, 1H, CH), 8.34 (s, 1H, CH), 
6.29 (d, 1H, CH, J = 5.3 Hz), 5.85 (t, 1H, CH, J = 5.49 Hz), 5.68 (dd, 1H, CH, J = 5.67 
Hz, 4.0 Hz), 5.14 (dd, 1H, CH, J = 8.8 Hz, 2.7 Hz), 5.07 (d, 1H, CH, J = 2.7 Hz), 4.52 
(m, 2H, CH, NH), 3.68 (s, 1H, CH), 2.14 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.01 (s, 3H, 
CH3), 2.04 (m, 1H, CH), 0.94 (d, 3H, CH3, J = 2.5 Hz), 0.91 (d, 3H, CH3, J = 2.4 Hz)  
 
4.2.8. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetra hydrofuran-2-
yl)methyl ((2S,3R)-2,3-dihydroxy-4-methylpentanoyl) sulfamate (12).  
Compound 11 (0.056 mmol) was dissolved in 0.02 M sodium methoxide solution in 
methanol (3 mL) and stirred for 2 h at room temperature. DOWEX 50WX8 hydrogen 
form resin (10 mg) was added in portions, filtered and concentrated to afford compound 
12 (0.03 mmol). Yield 56%, white solid; 1H-NMR (600MHz, CD3OD) δ 8.52 (s, 1H, CH), 
8.18 (s, 1H, CH), 6.08 (d, 1H, CH, J = 2.8 Hz), 4.64 (t, 1H, CH, J = 2.5 Hz), 4.40 (m, 
1H, CH), 4.31 (m, 3H, CH), 4.05 (d, 1H, CH, J = 1.0 Hz), 3.51 (dd, 1H, CH, J = 4.4 Hz, 
1.0 Hz), 1.86 (m, 1H, CH), 1.01 (d, 3H, CH3, J = 3.2 Hz), 0.94 (d, 3H, CH3, J = 3.2 Hz); 
HRMS-ESI m/z [M+H]+ C16H24N6O9SH+ calcd 477.1325, Found: 477.1395. 
 
4.2.9. (2R,3R,4S,5R)-2-(6-amino-2-iodo-9H-purin-9-yl)-5-(hydroxyl 
methyl)tetrahydrofuran-3,4-diol (14).  
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Compound 14 was prepared by following the reported procedure.34 Yield 11% in 4 steps, 
yellow solid; 1H-NMR (300MHz, CD3OD) δ 8.20 (s, 1H, CH), 5.89 (d, 1H, CH, J = 6.03 
Hz), 4.66 (t, 1H, CH, J = 5.31 Hz), 4.30 (dd, 1H, CH, J = 5.10 Hz, 3.09 Hz), 4.15-4.12 
(m, 1H, CH), 3.88 (dd, 1H, CH, J = 12.45 Hz, 2.73 Hz), 3.74 (dd, 1H, CH, J = 12.45 Hz, 
2.94 Hz), 2.18 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.11 (s, 3H, CH3) 
 
4.2.10. (2R,3R,4R,5R)-2-(6-amino-2-iodo-9H-purin-9-yl)-5-(hydroxy 
methyl)tetrahydrofuran-3,4-diyl diacetate (15).  
Compound 15 was prepared by following the procedure described for compounds 8 and 
9. Yield 67% in 3 steps, colorless oil; 1H-NMR (300MHz, CDCl3) δ 7.77 (s, 1H, CH), 
6.47 (br, 1H, OH), 5.97 (d, 1H, CH, J = 7.68 Hz), 5.91 (m, 1H, CH), 5.67 (dd, 1H, CH, J 
= 5.13 Hz, 1.29 Hz), 4.36 (d, 1H, CH, J = 1.08 Hz), 4.51 (dd, 1H, CH, J = 13.02 Hz, 1.47 
Hz), 3.88 (d, 1H, CH, J = 11.73 Hz), 2.17 (s, 3H, CH3), 2.11 (s, 3H, CH3) 
 
4.2.11. (2R,3R,4R,5R)-2-(6-amino-2-iodo-9H-purin-9-yl)-5-((sulfamoyl 
oxy)methyl)tetrahydrofuran-3,4-diyl diacetate (16).  
Compound 16 was prepared by following the procedure described for compound 10. 
Yield 86%, white solid; 1H-NMR (300MHz, CDCl3) δ 7.93 (s, 1H, CH), 6.14 (d, 1H, CH, 
J = 5.49 Hz), 5.84 (br, 2H, NH2), 5.78 (t, 1H, CH, J = 5.31 Hz), 5.71 (t, 1H, CH, J = 4.02 
Hz), 4.53 (d, 2H, CH2, J = 3.48 Hz), 4.47 (m, 1H, CH), 2.16 (s, 3H, CH3), 2.09 (s, 3H, 
CH3) 
 




diacetate (17).  
Compound 17 (0.03 mmol) was prepared by following the procedure described for 
compound 11. Yield 81%, white solid; 1H-NMR (300MHz, CDCl3) δ 8.31 (s, 1H, CH), 
6.28 (d, 1H, CH, J = 6.69 Hz), 5.75 (m, 1H, CH), 5.54 (m, 1H, CH), 4.70 (m, 1H, CH), 
4.42-4.34 (m, 2H, CH2), 2.14 (s, 3H, CH3), 1.98 (s, 6H, CH3), 1.64 (m, 2H, CH2), 1.50 
(m, 1H. CH), 0.79(dd, 6H, CH3, J = 13.17 Hz, 6.60 Hz) 
 
4.2.13. ((2R,3S,4R,5R)-5-(6-amino-2-iodo-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl ((S)-2-hydroxy-4-methylpentanoyl) sulfamate (18).  
Compound 18 was prepared by following the procedure described for compound 12. 
Yield 67%, white solid; 1H-NMR (500MHz, CD3OD) δ 8.26 (s, 1H, CH), 5.98 (d, 1H, 
CH, J = 4.90 Hz), 4.55 (t, 1H, CH, J = 4.85 Hz), 4.50 (dd, 1H, CH, J = 11.20 Hz, 2.80 
Hz), 4.44 (dd, 1H, CH, J = 11.2 Hz, 3.40 Hz), 4.36 (t, 1H, CH, J = 4.70 Hz), 4.28 (q, 1H, 
CH, J = 3.60 Hz), 4.03 (t, 1H, CH, J = 6.30 Hz), 1.83-1.79 (m, 1H, CH), 1.52-1.47 (m, 
2H, CH2), 0.90 (dd, 6H, CH3, J = 6.60 Hz, 2.25 Hz); HRMS-ESI m/z [M+H]+ 
C16H23IN6O8SH+ calcd 587.0343, Found 587.0410. 
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IV. Part 2-2. Structure Activity Relationship (SAR) Studies of 
Leucyladenylate Sulfamates as a Novel LRS-targeted 
mTORC1 Inhibitors 
 
1. Design background & strategy 
Previously, we designed a new series of compounds based on the structure of aminoacyl 
adenylate which is well known enzymatic reaction intermediate of ARSs and reported the 
three representative compounds among the library of leucyladenylate sulfamates. Here in, 
we describe the synthesis and inhibitory activities against mTORC1 of other 
leucyladenylate sulfamtes and structure-activity relationship of leucyladenylate sulfamte 
derivatives. We modified adenine, ribose ring and leucyl side chains moieties and 
evaluated their biological activity. In R1 group, we introduced N6-methylamino group and 
oxygen instead of N6-amino group of adenine and 2-cholro, 2-iodo and alkyl chain for R2 
group modification. Also, we designed arabinose, 2’-deoxy ribose, 3’-deoxy ribose, 3’-
deoxy-3’amino ribose and bicyclic structure of 3’-deoxy-3’-amino ribose for the ribose 
ring part. Furthermore, for the leucyl side chain modification, we substituted (S)-amino 
group in α-position of leucine with (S)-hydroxyl, (R)-hydroxyl, (S)-chloro, (S)-thio 
hydroxyl groups etc. and synthesized the leucyladenylate sulfamte derivatives and 
evaluated suppression of mTORC1 activation.  
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Figure 15. (2S,3R)-2,3-dihydroxy-4-methylpentanoylsulfamoyl adenylate (1) and its 
derivatives for SAR study. 
 
2. Result and Discussion 
2.1. Chemistry 
Synthesis of (2S,3R)-2,3-diacetoxy-3-cyclopropylpropanoic acid (52) began with 
commercially available cyclopropane carboxaldehyde (46) as illustrated in scheme 7. 
Aldol reaction of aldehyde 46 with benzyl acetate provided β-hydroxy ketone 47. After 
introducing mesyl leaving group, condensation reaction under basic condition provided 
α, β-unsaturated ketone 49. Sharpless asymmetric dihydroxylation followed by 
acetylation and debenzylation produced compound 52. 
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Scheme 7. Synthesis of (2S,3R)-2,3-diacetoxy-3-cyclopropylpropanoic acid (52). 
Reagents & conditions: (a) LHMDS, anhyd.THF, -78
 o
C, overnight, 52%; (b) MsCl, 
TEA, MC, 0 
o
C to r.t, overnight, 56%; (c) DBU, DMF, 0 
o
C to r.t, 2 h, 99%; (d) AD 
Mix β, H2O:t-BuOH = 1:1, r.t, 12 h, 79%; (e) Ac2O, TEA, DMAP, ACN, r.t, 12 h, 96%; 
(f) Pd/C, H2, MeOH, r.t, 2 h, 99%. 
 
(S)-2-(acetylthio)-4-methylpentanoic acid (57) was prepared from commercailly 
available D-α-Hydroxy isocaproic acid (53) in 4 steps as described in scheme 8. After 
benzyl protection of carboxylic acid, mesylate group was converted to thioacetate group 




Scheme 8. Synthesis of (S)-2-(acetylthio)-4-methylpentanoic acid (57). 
Reagents & conditions: (a) (i) Cs2CO3, MeOH/H2O (5:1), r,t, 30 min (ii) BnBr, DMF, 0 
o
C to r.t, 12 h, 99%; (b) MsCl, TEA, MC, 0 
o
C to r.t, 2 h, 99%; (c) KSAc, ACT, reflux, 5 
h, 99%; (d) BCl3, CH2Cl2, -78 
o
C to 0 
o
C, 1 h, 40%. 
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Compounds 63 and 65 were prepared from commercially available 4-methyl-2-pentenoic 
acid (58) in 5 steps as shown in scheme 9. Sharpless asymmetric dihydroxylation 
provided compound 60, monomethylation of α-hydroxyl group provided compound 61, 
then acetylation and deprotection of the benzyl group produced (2S,3R)-3-acetoxy-2-
methoxy -4-methylpentanoic acid (63). Methylation of β-hydroxyl group of compound 
60 produced dimethoxy product 64 followed by deprotection of the benzyl group afforded 
(2S,3R)-2,3-dimethoxy-4-methylpentanoic acid (65). 
 
 
Scheme 9. Synthesis of (2S,3R)-3-acetoxy-2-methoxy -4-methylpentanoic acid (63) and 
(2S,3R)-2,3-dimethoxy-4-methylpentanoic acid (65). 
Reagents & conditions: (a) K2CO3, BnBr, ACT, reflux, overnight, 99%; (b) AD mix β, 
H2O:t-BuOH, r.t, overnight, 87%; (c) Ag2O, MeI, CH2Cl2, refux, 36 h, 20%; (d) Ag2O, 
MeI, CH2Cl2, refux, 36 h, 69%;(f) Pd/C, H2, Methanol, 99%. 
 
Synthesis of leucyladenylate sulfamate derivatives 3, 5, 8, 20, 25-31, 38, 40, 43 were 
carried out as illustrated in Scheme 10. Sulfamate intermediate 66 was prepared following 
a previous report.32 Amide coupling between compound 66 and the protected chiral acids 
and pyrazole-5-carboxylic acid derivatives produced intermediates 67-80, protection 
groups of each compounds were then removed to produce the corresponding final 
compounds. 
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Scheme 10. Synthesis of aminoacyladenylate analogues. 
Reagents & conditions: (a) corresponding acid, DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h, 
45~80%; (b) 0.02 M NaOMe in MeOH, r.t, 2 h, 68~85%. 
 
Synthesis of N6-methyladenylate analogues is illustrated in scheme 11. N6-
methyladenosine (84) was synthesized from adenosine (81) in 3 steps, then corresponding 
5’-O-sulfamoylated intermediate 87 was prepared by same route described in scheme 5. 
(2R,3S)-dihydroxy-4-methylpentanoic acid (DMPA) protected by O-diacetyl was 
prepared from commercially available 4-methyl-2-pentenoic acid in 4 steps by Sharpless 
asymmetric dihydroxylation, and its configuration was confirmed by following 
previously described procedures.38 (2S)-hydroxyisocaproic acid (HICA, L-leucic acid) 
protected by O-acetyl was prepared by acetylation of commercially available L-leucic 
acid. Amide coupling between compound 87 and the corresponding protected chiral acids 
produced compounds 88 and 89, respectively. Acetyl groups of which were then removed 
in the presence of sodium methoxide to yield the final compounds 2 and 35. A peptide 
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coupling reaction between compound 87 and commercially available (S)-2-chloro-4-




Scheme 11. Synthesis of N6-methyladenylate analogues. 
Reagents & conditions: (a) Ac2O, pyidine, 60 
o
C, 8 h; (b) CH3Br, DBU, MeCN, r.t. (c) 
7M NH3 in MeOH (d) MMTCl, anhyd. pyridine, anhyd. DMF, 0 
o
C to r.t, 24 h; (e) Ac2O, 
TEA, DMAP, CH3CN, 0 
o
C to r.t, 4 h; (f) 80% aq. AcOH, r.t, 12 h; (g) i) NaH, anhyd. 
THF, 0 
o
C, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 
o
C to r.t, 5 h; (h) chiral acid, DCC, DMAP, 
anhyd. CH2Cl2, r.t, 12 h; (i) 0.02 M NaOMe in MeOH, r.t, 2 h. 
 
Synthesis of 2’-deoxyadenylate analogues is shown in scheme 12. 5’-O-sulfamoylated 
intermediate 94 was prepared in 4 steps following the same route described in scheme 5. 
DCC coupling with corresponding protected chiral acids provided intermediates 95-100, 
- 40 - 
 
then removal of protection groups yielded each final compounds. 
 
 
Scheme 12. Synthesis of 2’-deoxyadenylate analogues. 
Reagents & conditions: (a) MMTCl, anhyd. pyridine, anhyd. DMF, 0 oC to r.t, 24 h, 53%; 
(b) Ac2O, TEA, DMAP, CH3CN, 0 oC to r.t, 4 h, 89%; (c) 80% aq. AcOH, r.t, 12 h, 48%; 
(d) i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 oC to r.t, 5 h, 77%; (e) 
chiral acid, DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h, 25~45%; (f) 0.02M NaOMe in MeOH, 
r.t, 2 h, 30~50%. 
 
5’-O-sulfamoylated 2-iodoadenosine (101) was synthesized from guanosine in 4 steps by 
following the route described in Scheme 6. Peptide coupling between compound 101 and 
the protected chiral acids and pyrazole-5-carboxylic acid derivatives produced 
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intermediates 102-105 followed by deprotection of four acetyl groups produced 
corresponding final compounds 6, 16, 19 and 21. 
 
 
Scheme 13. Synthesis of 2-iodoadenylate analogues. 
Reagents & conditions: (a) corresponding acid, DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h, 
45~80%; (b) 0.02 M NaOMe in MeOH, r.t, 2 h, 68~85%. 
 
Synthesis of 3’-deoxyadenylate analogues is illustrated in scheme 14. 3’-deoxyadenosine 
(109) was prepared from adenosine (81) in 5 steps. Selective tert-butyldimethylsilane 
(TBDMS) protection of 2’ and 5’-hydroxyl group of adenosine provided compound 106. 
Barton-McCombie deoxygenation reaction of 3’-hydroxyl group afforded compound 108 
followed by removal of two TBDMS groups afforded compound 109. 5’-O-sulfamoylated 
3’-deoxyadenosine (113) was synthesized in 4 steps, selective tert-butyldiphenylsilane 
(TBDPS) protection of 5’-hydroxyl group, acetylation, selective deprotection of TBDPS 
group followed by sulfamoylation provided compound 113. Amide coupling with 
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corresponding protected chiral acids afforded intermediates 114 and 115 and removal of 
acetyl groups yielded compounds 7 and 36, respectively. 
 
 
Scheme 14. Synthesis of 3’-deoxyadenylate analogues. 
Reagents & conditions: (a) TBSCl, pyridine, r.t, 48 h; (b) TEA, MeOH, r.t, overnight, 55% 
in 2 steps ; (c) thiocarbonylimidazole, DMAP, CH2Cl2, r.t, overnight, 93%; (d) n-Bu3SnH, 
AIBN, toluene, reflux, 6 h, 91%; (e) TBAF, THF, 0 
o
C to r.t, overnight, 87%; (f) TBDPSCl, 
TEA, DMF, DMAP, r.t, overnight, 73%; (g) Ac2O, pyridine, 60 
o
C, 8 h, 93%; (h) TBAF, 
THF, 0 
o
C, 1 h, 89%; (i) NH2SO2Cl, NaH, anhyd. THF, 0 
o
C to r.t, 5 h, 75%; (j) chiral 
acid, DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h, 65% for 114, 69% for 115; (k) 0.02 M 
NaOMe in MeOH, r.t, 2 h, 65% for 7, 30% for 36. 
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Synthesis of adenine arabinose analogues was carried out as illustrated in scheme 15. 5’-
O-sulfamoylated intermediate 119 was prepared from commercially available adenine 9-
β-D-arabinofuranoside (116) as described in scheme 5. Peptide coupling with prepared 
side chains provided compounds 120-122 followed by deprotection of acetyl groups 
afforded final compounds 9, 10 and 17, respectively. 
 
 
Scheme 15. Synthesis of adenine arabinose analogues. 
Reagents & conditions: (a) MMTCl, anhyd. pyridine, anhyd. DMF, 0 oC to r.t, 24 h; (b) 
acetic anhydride, TEA, DMAP, CH3CN, 0 oC to r.t, 4 h; (c) 80% aq. AcOH, r.t, 12 h; (d) 
i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 oC to r.t, 5 h; (e) chiral acid, 
DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h; (f) 0.02 M NaOMe in MeOH, r.t, 2 h. 
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Synthesis of 2-chloroadenylate analogues was synthesized as shown in scheme 16. 5’-O-
sulfamoylated intermediate 126 was prepared from commercially available 2-
chloroadenosine (123) in 4 steps as described in scheme 5. Peptide coupling with 
prepared side chains provided compounds 127-129 followed by deprotection of acetyl 
groups afforded final compounds 11-13, respectively. An amide coupling reaction 
between compound 126 and commercially available (S)-2-chloro-4-methylpentanoic acid 
followed by deprotection of the acetyl groups provided the final compound 18. 
 
 
Scheme 16. Synthesis of 2-chloroadenylate analogues. 
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Reagents & conditions: (a) MMTCl, anhyd. pyridine, anhyd. DMF, 0 oC to r.t, 24 h; (b) 
acetic anhydride, TEA, DMAP, CH3CN, 0 oC to r.t, 4 h; (c) 80% aq. AcOH, r.t, 12 h; (d) 
i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 oC to r.t, 5 h; (e) chiral acid, 
DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h; (f) 0.02M NaOMe in MeOH, r.t, 2 h. 
 
Synthesis of inosine analogues is shown in scheme 17. 5’-O-sulfamoylated intermediate 
133 was prepared in 4 steps following the same route described in scheme 5. DCC 
coupling with corresponding protected chiral acids provided intermediates 134-138, then 
removal of protection groups yielded final compounds 14, 15, 23, 24 and 45, respectively. 
 
 
Scheme 17. Synthesis of inosine analogues. 
Reagents & conditions: (a) MMTCl, anhyd. pyridine, anhyd. DMF, 0 oC to r.t, 24 h; (b) 
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acetic anhydride, TEA, DMAP, CH3CN, 0 oC to r.t, 4 h; (c) 80% aq. AcOH, r.t, 12 h; (d) 
i) NaH, anhyd. THF, 0 oC, 1 h, ii) NH2SO2Cl, anhyd. THF, 0 oC to r.t, 5 h; (e) chiral acid, 
DCC, DMAP, anhyd. CH2Cl2, r.t, 12 h; (f) 0.02M NaOMe in MeOH, r.t, 2 h. 
 
Synthesis of 3’-amino-3’-deoxyadenylate analogue 32 is shown in scheme 18. 
Isopropylidene protection of 1’ and 2’-hydroxyl group and TBDPS protection of 5’-
hydroxyl group of commercially available D-xylose provided compound 141. 3’-Triflate 
group was substituted with azido group with inversion of stereochemistry to afford 
compound 143. Isopropylidene group was removed and acetyl groups were introduced 
simultaneously at the same condition to give compound 144. Condensation reaction of 
compound 144 with 6-chloropurine provided desired β-form 145 with 50% yield. After 
removal of acetyl group, azido group was reduced to give compound 147. N-Boc 
protection followed by cyclization under basic condition provided compound 149. 5’-O-
sulfamoylated intermediate 151 was prepared by TBDPS deprotection and 
sulfamoylation of compound 149. An amide coupling with commercially avaiable N-Boc 
leucine afforded compound 152 followed by removal of carbamate group and N-Boc 
protection group yielded the final compound 32. 
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Scheme 18. Synthesis of compound 32. 
(a) CuSO4, Me2CO, H2SO4, r,t, 24 h, 30%; (b) TBDPSCl, imidazole, DMAP, DMF, 0 oC 
to r.t, overnight, 57%; (c) (CF3SO2)2O, pyridine, MC, -10 oC, 30 min, 80% (d) NaN3, 
pyridine, DMF, r.t, 7 days, 65%; (e) Ac2O, AcOH, H2SO4, 0 oC, 1 h, 95%; (f) (i) 6-
chloropurine, HMDS, (NH4)2SO4, reflux, 24 h, (ii) TMSOTf, anhyd. CH2Cl2, r.t, 68 h, 
50%; (g) NH3 2 M in MeOH, r.t, 24 h, 77%; (h) Lindlar catalyst, H2, MeOH, r.t, overnight; 
(i) Boc2O, Na2CO3, THF:H2O = 4:1, 0 oC to r.t, overnight, 53% (j) 2 N NaOH, 
THF:MeOH = 1:1, r.t, overnight, 60%; (k) TBAF, THF, 0 oC to r.t, overnight, 99%; (l) 
NH2SO2Cl, NaH, anhyd. THF, 0 oC to r.t, 5 h, 82%; (m) N-Boc-Leu, DCC, DMAP, anhyd. 
THF, r.t, 12 h, 64%; (n) 1 N NaOH, THF, r.t, 48 h; (o) 1 N HCl in MeOH, r.t, overnight. 
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Scheme 19. Synthesis of 3’-amino-3’-deoxyadenylate analogues. 
(a) TBDPSCl, dry pyridine, r.t, 40 h, 79%; (b) AcOCMe2COBr, ACN, 0.8 eq.H2O, 0'C, 5 
h, 78%; (c) K2CO3, MeOH, 0 oC, 48 h, 81%; (d) BnNCO, toluene, 90'C, overnight, 80%; 
(e) NaH, anhyd.THF, -20 oC, 1 h, 99%; (f) KBr, Oxone, ACN, 70 oC, 24 h, 63%; (g) TBAF, 
anhyd. THF, 0 oC to r.t, 2 h, 90%; (h) NH2SO2Cl, NaH, anhyd. DMF, 0 oC to r.t, 12 h, 
76%; (i) chiral acid, DCC, DMAP, anhyd. THF:DMF, r.t, 12 h, 44% for 160, 55% for 161 
(j) 0.02 M NaOMe, r.t, 4 h, 90% for 22, 87% for 44. 
 
Synthesis of 3’-amino-3’-deoxyadenylate analogues is illustrated in scheme 19. 
Compound 158 was prepared in 5 steps from adenosine (81) by following a previously 
reported procedures.41 Oxidative debenzylaion of N-benzyl amide was carried out by a 
bromo radical formed through the oxidation of potassium bromide under mild condition.42 
Removal of 5’-TBDPS group and sulfamoylation provided 5’-O-sulfamoylated 
intermediate 151. Amide coupling with corresponding protected chiral acids afforded 
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compounds 160 and 161 followed by deprotection of acetyl groups yielded final 
compounds 22 and 44, respectively. 
 
2.2. Biological Activity 
To evaluate the effect of the synthesized compounds on cellular mTORC1 pathway, we 
first determined leucine-induced phosphorylation of S6Kinase (S6K) in HEK293 cells by 
immunoblots. For a primary screening, we pretreated HEK293 cells with compounds 2-
45 at one fixed concentration (200 µM) as well as with compound 1, rapamycin (100 nM) 
and leucinol (800 µM) for comparison, and then activated mTORC1 by treating the cells 
with leucine for 10 min. As shown in Figure 16, leucine induced phosphorylation of S6K, 
demonstrating an intense band that corresponds to pS6K whereas rapamycin and 
compound 1 inhibited S6K phosphorylation. Among the tested compounds, compounds 
4 and 5 appeared to show more potent inhibition of S6K phosphorylation than compound 
1, while compounds 1 and 2 appeared to inhibit S6K phosphorylation to a similar extent 
as compound 1.  
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Figure 16. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 2-5 at fixed concentrations (200 µM). Rapamycin was treated at 100 nM, 
leucinol was at 800 µM. 
 
Next, we focused on the compounds 4 and 5 and confirmed the dose-dependent inhibition 
of S6K phosphorylation (Figure 17). Compound 4 inhibited S6K phosphorylation in a 
dose-dependent manner, while compound 5 showed dose-dependent inhibition except at 
200 µM concentration. When 2’-hydroxyl group or β-hydroxyl group of the leucyl side 
chain is removed, the activity of mTORC1 inhibition enhanced than compound 1 in both 
case. According to the result, 2’-hydroxyl group is not necessary to mTORC1 inhibition 
and also, (S)-2-hydroxy-4-methylpentanoyl side chain has favorable effect on the 
mTORC1 inhibition. 
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Figure 17. Dose dependent inhibition of mTORC1 activation by compounds 4 and 5. 
 
Next, we examined the inhibition of mTORC1 activation with compounds 6 and 7 
(Figure 18). Compound 6 appeared to inhibit S6K phosphorylation to a similar extent as 
compound 1, while compound 7 did not inhibit S6K phosphorylation at the same 
concentration. When 2-iodo group is introduced in the adenine, the potency of mTORC1 
inhibition maintained. However, when 3’-hydroxyl group is removed, the potency of 
mTORC1 inhibition decreased, suggesting that 3’-hydroxyl group is essential in binding 
interaction in LRS catalytic site. 
- 52 - 
 
 
Figure 18. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 6 and 7 at fixed concentrations. 
 
Next, we determined the effects of compounds 8-11 on leucine-induced mTORC1 
activation using the immunoblotting method. As shown in Figure 19, compounds 8 and 
10 maintained the activity of mTORC1 inhibition to a same extent as compound 1 but, 
compounds 9 and 11 lost the activity. To our surprise, the inhibition of S6K 
phosphorylation maintained when both α, β-hydroxyl group were removed. When 
adenylate group is substituted with adenine arabinose, compound 10 which has α-
hydroxyl group in leucyl side chain showed more potent inhibition than compound 9 with 
both α- hydroxyl and β-hydroxyl group, which is in agreement with previous reported 
observation.30 Also, when 2-chloro group in introduced in adenine, it lost the activity at 
some extent, suggesting that 2-iodo group is crucial in the binging interaction in catalytic 
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site of LRS. 
 
 
Figure 19. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 8-11 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
Next, we examined the inhibition of mTORC1 activation with compounds 12-15. As 
shown in Figure 20, compound 12 appeared to inhibit S6K phosphorylation to a similar 
extent as compound 1, while compounds 13-15 demonstrated more potent inhibition than 
compound 1. According to the result, α-methoxy group has a favorable effect on the 
inhibition of S6K phosphorylation and α, β-methoxy group further enhanced the 
inhibition of S6K phosphorylation. Also, inosine derivatives showed potent inhibition of 
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mTORC1 activation in both compounds 14 and 15, which has α-hydroxyl group and α, 
β-hydroxyl group, respectively. Based on the band intensity of pS6K, compound 15 
appeared slightly more potent than compound 14, which is again in agreement with 
previous report.30 
 
Figure 20. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 12-15 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
Next, we examined the inhibition of mTORC1 activation with compounds 16-18 (Figure 
21). Based on band intensities of pS6K, when agrocin side chain is introduced, the 
inhibition of S6K phosphorylation enhanced slightly, suggesting structurally more rigid 
cyclopropyl group has favorable effect on the activity of mTORC1 inhibition. In the case 
of compound 18, when α-hydroxyl group is substituted with α-chloro group, intensity of 
inhibition of S6K phosphorylation increased extensively. It is interesting that 
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hydrophobic chloro group instead of hydrophilic hydroxyl group has favorable effect on 
the binding affinity in catalytic site of LRS. 
 
 
Figure 21. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 16-18 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
Next, we determined the effects of compounds 19-25 on leucine-induced mTORC1 
activation using the immunoblotting method. As shown in Figure 22, compounds 20-22 
appeared to inhibit mTORC1 activation to a similar extent as compound 1, while 
compounds 19, 23-25 did not inhibit mTORC1 activation. When 3-isopropyl-1-methyl-
1H-pyrazole-5-carboxylic acid group is coupled as a sulfonamide group with adenylate 
and 2-iodoadenylate, the activity of mTORC1 inhibition maintained. Also, compound 22 
which has both agrocin side chain and 3’-deoxy-3’-amino adenylate structure showed 
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similar extent of inhibition of mTORC1 activation. Inosine derivatives with (R)-hydroxyl 
group (23) or (S)-thiol group (24) instead of (S)-hydroxyl group at the α-position 
adversely affected on the activity of mTORC1 inhibition. 
 
 
Figure 22. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 19-25 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
Next, we examined the inhibition of mTORC1 activation with compounds 26-31 (Figure 
23). According to band intensities of pS6K, compounds 27, 29 and 30 appeared to inhibit 
S6K phosphorylation to a similar extent as compound 1, while compounds 26, 28 and 31 
showed less potent inhibition of S6K phosphorylation. When pyrazole group is 
introduced in leucyl side chain, only compound with 3-t-butyl pyrazole group (27) 
showed inhibition of mTORC1 activation, while compounds with 3-isopropyl (26) and 3-
cyclopropyl pyrazole (28) did not showed activity. Also, compounds with (R)-hydroxyl 
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group (29) or (S)-thiol group (30) instead of (S)-hydroxyl group at the α-position 
maintained the activity, which is an opposite result with that of inosine derivatives. 
Compound 31 with N-methyl amino group instead of (S)-hydroxyl group slightly less 
potent inhibition than compound 1. 
 
 
Figure 23. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 26-31 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
Next, we assessed the inhibition of mTORC1 activation with compounds 32-34. As 
shown in Figure 24, all compounds showed less potent inhibition of S6K phosphorylation. 
Both 3’-deoxy-3’-aminoadenylate and 2’-deoxyadenylate with leucyl side chain did not 
inhibit S6K phosphorylation and 2’-deoxyadenylate with (2R,3S)-α,β-dihydroxyl side 
chain also lost activity.  
Next, we examined the inhibition of mTORC1 activation with compounds 35-39. As 
shown in Figure 25, all compounds did not show more potent inhibition of S6K 
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phosphorylation than compound 1. Both N6-methyladenylate and 3’-deoxyadenylate with 
α-hydroxyl side chain did not inhibit mTORC1 activation and also, 2’-deoxyadenylate 
with α-hydroxyl group and α-methoxy-β-hydroxyl group did not show potent inhibition 
than compound 1. 
 
 
Figure 24. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 32-34 at fixed concentration. 
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Figure 25. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 35-39 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
 
 
Figure 26. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds 40-45 at fixed concentrations (200 µM). Rapamycin was treated at 100 
nM, leucinol was at 800 µM. 
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Next, we assessed the inhibition of mTORC1 activation with compounds 40-45 (Figure 
26). According to the band intensities of pS6K, all compounds did not inhibit S6K 
phosphorylation when compared to leucinol. Compounds 40 and 41 with α-chloro group 
adversely affected on the activity of mTORC1 inhibition, which is an opposite result with 
that of 2-chloroadnylate (18). Compounds with α, β-dimethoxy group (42, 43) did not 
show mTORC1 inhibition and when agrocin side chain is introduced in inosine derivative 
(45), the activity also did not improved. 
 
3. Conclusion 
We have developed leucyladenylate sulfamate derivatives that directly interact with LRS 
to inhibit the mTORC1 pathway.30 Based on these previous findings, we synthesized a 
library of leucyladenylate sulfamates by modifying adenine (group 1), ribose (group 2) 
and leucine moieties (group 3) and evaluated their biological activity. When we tested 
these compounds by using immunoblots, we found that group 1 compounds with a 
lipophilic group generally showed good activity against mTORC1, while 2-iodoadenylate 
derivatives were most active. Inosine derivatives also showed good inhibition against 
mTORC1 activity, which is a same trend with 2-iodoadenylate derivatives. On the other 
hand, any modifications in the ribose moiety (group 2) lead to the loss of activity when 
compared to the most potent previously reported compound.30 Among the adenylate 
derivatives, compound 5 with α-hydroxyl group was most potent. However, among the 
2’-deoxyadeylate derivatives, compound 4 with α, β-hydroxyl group was most active. In 
the case of arabinose derivatives, compound with agrocin side chain (17) showed potent 
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activity. Among the group 3 compounds, generally replacement of the α-amino group of 
leucine with a hydroxyl group significantly enhanced inhibitory activity against mTORC1, 
while introduction of an additional hydroxyl group also resulted in good inhibitory effect. 
According to the biological activity result, the potency of inhibition of mTORC1 
activation depends on the combination of adenine, ribose ring and side chain structure.   
 
4. Experimental 
4.1. General Experimental 
All chemical reagents were commercially available. Melting points were determined on 
a Büchi Melting Point B-540 apparatus and are uncorrected. Silica gel column 
chromatography was performed on silica gel 60, 230-400 mesh, Merck. Nuclear magnetic 
resonance (1H-NMR and 13C-NMR) spectra were recorded on JEOL JNM-LA 300 [300 
MHz (1H), 75 MHz (13C)] and Bruker Avance 400 MHz FT-NMR [400 MHz (1H), 100 
MHz (13C)] spectrometers. Chemical shifts are reported in ppm units with Me4Si as a 
reference standard. Mass spectra were recorded on a VG Trio-2 GC-MS and 6460 Triple 
Quad LC/MS. All final compounds were purified to >95% purity, as determined by high-
performance liquid chromatography (HPLC). HPLC was performed on an Agilent 1120 
Compact LC (G4288A) instrument using an Agilent Eclipse Plus C18 column (4.6 x 250 
mm, 5 μm) and a Daicel Chiralcel OD-H column (4.6 x 250 mm, 5 μm). 
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4.2. Chemical spectra 
4.2.1. ((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-
yl)methyl ((2S,3R)-2,3-dihydroxy-4-methylpentanoyl)sulfamate (4) 
1H NMR (500 MHz, CD3OD): δ 8.49 (s, H8), 8.17 (s, H2), 6.49 (t, J = 6.80 Hz, H1’), 4.63 
(t, J = 2.75 Hz, H4’), 4.30-4.24 (m, H5’, H5”), 4.19 (q, J = 2.80 Hz, Hα), 4.10 (s, H3’), 3.48 
(d, 11.60 Hz, Hβ), 2.76 (qd, J = 6.30, 0.75 Hz, H2’), 2.47 (qd, J = 6.10, 3.05 Hz, H2”), 
1.90-1.83 (m, H٧), 1.01 (d, J = 6.60 Hz, 3H), 0.94 (d, J = 6.75 Hz, 3H), 13C NMR (125 
MHz, CD3OD): δ 182.3, 158.0, 154.6, 151.1, 142.0, 120.8, 87.4, 86.4, 80.5, 75.5, 73.7, 




yl)methyl ((S)-2-hydroxy-4-methylpentanoyl)sulfamate (5) 
1H NMR (500 MHz, CD3OD): δ 8.50 (s, H8), 8.19 (s, H2), 6.08 (d, J = 5.35 Hz, H1’), 4.64 
(t, J = 7.90 Hz, H2’), 4.38 (t, J = 3.80 Hz, H3’), 4.35-4.25 (m, H4’, H5’, H5”), 4.03 (dd, J = 
9.15, 3.25 Hz, Hα), 1.65-1.43 (m, 3H), 0.91 (t, J = 6.75 Hz, 6H), 13C NMR (125 MHz, 
CD3OD): δ 184.2, 158.0, 154.7, 151.5, 142.1, 120.8, 90.1, 85.1, 76.9, 73.8, 72.8, 69.9, 
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yl)methyl ((2S,3R)-2,3-dihydroxy-4-methylpentanoyl)sulfamate (7) 
1H NMR (500 MHz, CD3OD): δ 8.46 (s, H8), 8.18 (s, H2), 5.99 (d, J = 1.55 Hz, H1’), 4.70-
4.66 (m, H4’), 4.65-4.64 (m, H2’),  4.43 (dd, J = 11.25, 2.35 Hz, H5’), 4.26 (dd, J = 11.25, 
3.25 Hz, H5”), 4.11 (s, Hα), 3.51 (d, J = 8.10 Hz, Hβ), 2.40 (qd, J = 9.00, 5.65 Hz, H3’), 
2.11 (qd, J = 7.15, 4.45 Hz, H3”), 1.00 (d, J = 6.65 Hz, 3H), 0.94 (d, J = 6.75 Hz, 3H), 13C 
NMR (125 MHz, CD3OD): δ 182.4, 158.0, 154.5, 150.8, 141.8, 121.0, 93.7, 80.9, 80.4, 
77.8, 75.5, 70.8, 35.3, 32.8, 20.6, 20.3; MS (HR-ESI) m/z [M + H]+ calc. for C16H24N6O8S: 




1H NMR (500 MHz, CD3OD): δ 8.37 (s, 1H, Ar, 8H), 5.99 (d, 1H, CH, 1’H), 4.58 (t, 1H, 
CH, 2’H), 4.43 (qd, 2H, CH2, 5’H), 4.36 (t, 1H, CH, 3’H), 4.28 (q, 1H, CH, 4’H), 4.02 
(dd, 1H, CH), 1.81 (m, 1H, CH), 1.48 (m, 2H, CH2), 0.92 (s, 3H, CH3), 0.90 (s, 3H, CH3); 





1H NMR (500 MHz, CD3OD): δ 8.48 (s, 1H, Ar, 8H), 6.01 (d, 1H, CH, 1’H), 4.59 (t, 1H, 
CH, 2’H), 4.39 (t, 1H, CH, 3’H), 4.32 (qd, 2H, CH2, 5’H), 4.28 (q, 1H, CH, 4’H), 3.66 (d, 
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1H, CH), 3.47 (dd, 1H, CH), 3.36 (s, 3H, CH3), 1.85 (m, 1H, CH), 0.97 (d, 3H, CH3), 
0.90 (s, 3H, CH3) 13C NMR (125 MHz, CD3OD): δ 180.954, 158.805, 156.222, 152.858, 
142.248, 119.843, 90.102, 86.499, 85.249, 79.804, 77.057, 72.887, 69.893, 59.398, 





1H NMR (500 MHz, CD3OD): δ 8.49 (s, 1H, Ar, 8H), 6.01 (d, 1H, CH, 1’H), 4.61 (t, 1H, 
CH, 2’H), 4.38 (m, 1H, CH, 3’H), 4.34 (m, 2H, CH2, 5’H), 4.28 (m, 1H, CH, 4’H), 3.67 
(d, 1H, CH), 3.40 (s, 3H, CH3), 3.33 (s, 3H, CH3), 3.21 (m, 1H, CH), 1.91 (m, 1H, CH), 
0.97 (d, 3H, CH3), 0.89 (s, 3H, CH3), 13C NMR (125 MHz, CD3OD): δ 180.474, 158.866, 
156.234, 152.898, 142.267, 119.850, 90.298, 90.072, 86.315, 85.342, 77.040, 72.984, 






1H NMR (500 MHz, CD3OD): δ 8.42 (s, 1H, Ar, 2H), 8.04 (s, 1H, Ar, 8H), 6.05 (d, 1H, 
CH, 1’H), 4.62 (t, 1H, CH, 2’H), 4.38 (t, 1H, CH, 3’H), 4.18 (qd, 2H, CH2, 5’H), 4.28 (m, 
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1H, CH, 4’H), 4.05 (d, 1H, CH), 3.50 (dd, 1H, CH), 1.85 (m, 1H, CH), 1.01 (d, 3H, CH3), 
0.94 (s, 3H, CH3), 13C NMR (125 MHz, CD3OD): δ 182.163, 151.196, 149.741, 141.105, 
126.111, 90.217, 85.208, 80.462, 77.066, 75.527, 72.887, 69.811, 32.873, 20.585, 20.445; 
MS (HR-ESI) m/z [M + H]+ found 478.1230. 
 
4.2.8. ((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1,6-dihydro-9H-purin-9-
yl)tetrahydrofuran-2-yl)methyl ((S)-2-hydroxy-4-methylpentanoyl)sulfamate (15) 
1H NMR (500 MHz, CD3OD): δ 8.44 (s, 1H, Ar, 8H), 8.05 (s, 1H, Ar, 2H), 6.06 (d, 1H, 
CH, 1’H), 4.65 (t, 1H, CH, 2’H), 4.37 (m, 1H, CH, 3’H), 4.31 (m, 2H, CH2, 5’H), 4.28 
(m, 1H, CH, 4’H), 3.98 (dd, 1H, CH), 1.82 (m, 1H, CH), 1.54 (m, 1H, CH2), 1.43 (m, 1H, 
CH2), 0.91 (t, 6H, CH3), 13C NMR (125 MHz, CD3OD): δ 183.395, 160.102, 150.339, 
147.600, 140.740, 125.434, 89.557, 84.605, 76.233, 73.066, 72.219, 69.036, 45.601, 





1H NMR (500 MHz, CD3OD): δ 8.46 (s, 1H, Ar, 8H), 6.01 (d, J = 5.95 Hz, 1H, CH, 1’H), 
4.62 (t, J = 5.25 Hz, 1H, CH, 2’H), 4.36 (dd, J = 4.7, 3.15 Hz, 1H, CH, 3’H), 4.30 (m, 
2H, CH2, 5’H), 4.28 (m, 1H, CH2, 4’H), 4.22 (dd, J = 8.3, 6.05 Hz, 1H, CH), 1.78 (m, 
2H, CH2), 1.71 (m, 1H, CH), 0.91 (dd, J = 23.55, 6.3 Hz, 6H, CH3); MS (HR-ESI) m/z 
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[M + H]+ found 513.0705. 
 
4.2.10. ((3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2-iminohexahydrofuro[3,4-
d]oxazol-4-yl)methyl ((2S,3R)-3-cyclopropyl-2,3-dihydroxypropanoyl)sulfamate (22) 
1H NMR (500 MHz, CD3OD): δ 8.68 (s, 1H, Ar, 8H), 8.58 (s, 1H, Ar, 2H), 6.34 (s, 1H, 
CH, 1’H), 4.48 (t, J = 3.5, 1H, CH, 2’H), 4.43 (d, J = 2.3, 1H, CH, 3’H), 4.26 (m, 2H, 
CH2, 5’H), 4.20 (dd, J = 11.15, 3.75, 1H, CH, 4’H), 4.00 (m, 1H, CH), 3.09 (d, J = 8.8, 
1H, CH), 2.71 (dd, J = 8.97, 2.55, 1H, CH), 1.14 (m, 1H, CH), 0.57 (m, 1H, CH), 0.49 
(m, 1H, CH), 0.38 (m, 1H, CH), 0.30 (m, 1H, CH); MS (FAB) m/z 500 (M+H). 
 
4.2.11. ((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1,6-dihydro-9H-purin-9-
yl)tetrahydrofuran-2-yl)methyl ((R)-2-hydroxy-4-methylpentanoyl)sulfamate (23) 
1H NMR (500 MHz, CD3OD): δ 8.31 (s, 1H, Ar, 8H), 8.05 (s, 1H, Ar, 2H), 6.27 (s, 1H, 
CH, 1’H), 4.80 (s, 1H, CH, 2’H), 4.71 (t, J = 1.6, 1H, CH, 3’H), 4.56 (dd, J = 13.9, 2.35, 
1H, CH2, 4’H), 4.36 (m, 2H, CH2, 5’H), 4.05 (d, J = 5.45, 1H, CH), 1.85 (m, 1H, CH), 




yl)tetrahydrofuran-2-yl)methyl ((R)-2-mercapto-4-methylpentanoyl)sulfamate (24) 
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1H NMR (500 MHz, CD3OD): δ 8.36 (s, 1H, Ar, 8H), 8.06 (s, 1H, Ar, 2H), 6.06 (s, 1H, 
CH, 1’H), 4.43 (m, 1H, CH, 2’H), 4.40 (m, 1H, CH, 3’H), 4.33 (m, 2H, CH2, 5’H), 4.29 
(m, 1H, CH2, 4’H), 3.63 (m, 1H, CH), 1.78 (m, 1H, CH), ), 1.68 (m, 1H, CH), 1.49 (m, 
1H, CH), 0.90 (m, 6H, CH3); MS (HR-ESI) m/z [M + H]+ found 478.1056. 
 
4.2.13. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl ((2S,3R)-3-cyclopropyl-2,3-dihydroxypropanoyl)sulfamate (25) 
1H NMR (500 MHz, CD3OD): δ 8.51 (s, H8), 8.18 (s, H2), 6.08 (d, J = 5.60 Hz, H1’), 4.64 
(t, J = 5.30 Hz, H2’), 4.38 (dd, J = 8.20, 3.50 Hz, H3’), 4.35-4.27 (m, Hβ, H5’, H5”), 4.00 
(d, J = 2.10 Hz, Hα), 3.11 (dd, J = 9.10, 2.00 Hz, H4’), 1.17-1.11 (m, H٧), 0.56-0.29 (m, 
4H); MS (HR-ESI) m/z [M + H]+ calc. for C16H22N6O9S: 475.1247; found: 475.1245. 
 
4.2.14. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl ((R)-2-hydroxy-4-methylpentanoyl)sulfamate (29) 
1H NMR (500 MHz, CD3OD): δ 8.56 (s, 1H, Ar, 8H), 8.31 (s, 1H, Ar, 2H), 6.37 (s, 1H, 
CH, 1’H), 5.02 (d, J = 13.6, 1H, CH, 2’H), 4.75 (m, 2H, CH2), 4.38 (t, J = 4.8, 1H, CH), 
4.11 (d, J = 5.4, 1H, CH), 4.01 (m, 1H, CH), 1.84 (m, 1H, CH), ), 1.51 (m, 1H, CH), 0.90 
(t, J = 5.6, 6H, CH3); MS (HR-ESI) m/z [M + H]+ found 461.1442(M+H)+ 
 
4.2.15. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl (methyl-L-leucyl)sulfamate (31) 
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1H NMR (500 MHz, CD3OD): δ 8.51 (s, 1H, Ar, 8H), 8.19 (s, 1H, Ar, 2H), 6.08 (d, J = 
5.70, 1H, CH, 1’H), 4.65 (t, J = 5.3, 1H, CH, 2’H), 4.39 (m, 1H, CH, 3’H), 4.32 (m, 2H, 
CH2, 5’H), 4.28 (m, 1H, CH2, 4’H), 3.12 (t, J = 7.7, 1H, CH), 2.39 (s, 3H, CH3), 1.73 (m, 
1H, CH), 1.56 (m, 1H, CH), 1.38 (m, 1H, CH), 0.90 (dd, J = 27.9, 6.1, 6H, CH3); MS 
(HR-ESI) m/z [M + H]+ found 474.1773. 
 
4.2.16. ((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-
yl)methyl ((2R,3S)-2,3-dihydroxy-4-methylpentanoyl)sulfamate (34) 
1H NMR (500 MHz, CD3OD): δ 8.51 (s, H8), 8.18 (s, H2), 6.49 (t, J = 6.85 Hz, H1’), 4.63-
4.62 (m, H4’), 4.30-4.24 (m, H3’, Hα), 4.19 (d, J = 3.70 Hz, H5’), 4.06 (d-like, H5”), 3.5 (dd, 
J = 8.85, 1.25 Hz, Hβ),  2.75 (qd, J = 7.25, 3.60 Hz, H2’), 2.46 (qd, J = 6.05, 3.10 Hz, 
H2”), 1.88-1.81 (m, Hγ), 0.99 (d, J = 6.70 Hz, 3H), 0.94 (d, J = 6.70 Hz, 3H). 13C NMR 
(125 MHz, CD3OD): δ 182.2, 158.0, 154.5, 151.1, 142.1, 120.8, 87.55, 86.3, 80.6, 75.4, 
73.7, 70.1, 42.4, 32.9, 20.6, 20.4;MS (HR-ESI) m/z [M + H]+ calc. for C16H24N6O8S: 
461.1454; found: 461.1408. 
 
4.2.17. ((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-
yl)methyl ((S)-2-hydroxy-4-methylpentanoyl)sulfamate (36) 
1H NMR (300 MHz, CD3OD): δ 8.45 (s, H8), 8.18 (s, H2), 5.99 (d, J = 1.83 Hz, H1’), 4.71-
4.65 (m, H4’, H2’), 4.44 (dd, J = 11.34, 2.55 Hz, H5’), 4.27 (dd, J = 11.19, 3.30 Hz, H5”), 
4.08 (dd, J = 9.15, 3.66 Hz, Hα), 2.41 (qd, J = 8.97, 2.49 Hz, H3’), 2.11 (qd, J = 6.03, 2.88 
Hz, H3”), 1.82-1.80 (m, Hβ), 1.60-1.42 (m, Hβ”, Hγ), 0.91 (d, J = 2.58 Hz, 3H), 0.89 (d, J 
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= 2.73 Hz, 3H). 
 
4.2.18. ((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-
yl)methyl ((S)-2-hydroxy-4-methylpentanoyl)sulfamate (37) 
1H NMR (600 MHz, CD3OD): δ 8.47 (s, H8), 8.18 (s, H2), 6.49 (dd, J = 7.32, 5.94 Hz, 
H1’), 4.62 (quintet, J = 2.76Hz, H4’), 4.28-4.23 (m, H5’, H5”), 4.20 (q, J = 3.66 Hz, H3’), 
3.99 (dd, J = 9.60, 3.18 Hz, Hα), 2.77 (qd, J = 7.80, 6.00 Hz, H2’), 2.46 (qd, J = 5.94, 0.60 
Hz, H2”), 1.86-1.80 (m, Hγ), 1.57 (qd, J = 9.18, 3.66 Hz, Hβ), 1.45 (qd, J = 9.60, 5.04 Hz, 
Hβ), 0.92 (d, J = 6.36 Hz, 3H), 0.90 (d, J = 6.90 Hz, 3H). 13C NMR (125 MHz, CD3OD): 
δ 184.1, 158.0, 154.6, 151.1, 142.0, 120.9, 87.5, 86.5, 73.8, 70.2, 46.4, 42.3 (2C), 26.5, 




yl)methyl ((2S,3R)-3-hydroxy-2-methoxy-4-methylpentanoyl)sulfamate (38) 
1H NMR (300 MHz, CD3OD): δ 8.46 (s, H8), 8.19 (s, H2), 6.08 (d, J = 5.31 Hz, H1’), 4.66 
(t, J = 5.49 Hz, H2’), 4.40-4.28 (m, H3’, H4’, H5’, H5”), 3.70 (d, J = 3.48 Hz, Hα), 3.42-3.41 
(m, Hβ), 3.33 (s, 3H), 1.88-1.81 (m, Hγ), 0.98 (d, J = 6.78 Hz, 3H), 0.91 (d, J = 6.78 Hz, 
3H).  
4.2.20. ((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-
yl)methyl ((2S,3R)-2,3-dimethoxy-4-methylpentanoyl)sulfamate (42) 
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1H NMR (300 MHz, CD3OD): δ 8.36 (s, 1H), 8.14 (s, 1H), 6.39 (t, J = 6.60 Hz, 1H), 4.55 
(quintet, J = 2.94 Hz, 1H), 4.39-4.28 (m, 2H), 4.13 (q, J = 3.27 Hz, 1H), 3.63 (d, J = 3.12 
Hz, 1H), 3.28 (s, 3H), 3.21 (s, 3H), 3.10 (dd, J = 7.68, 3.87 Hz, 1H), 2.70 (quintet, J = 
7.14 Hz, 1H), 2.43-2.32 (m, 1H), 1.89-1.77 (m, 1H), 0.87 (d, J = 6.60 Hz, 3H), 0.80 (d, J 
= 6.78 Hz, 3H). 
 
4.2.21. ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl ((2S,3R)-2,3-dimethoxy-4-methylpentanoyl)sulfamate (43) 
1H NMR (300 MHz, CD3OD): δ 8.42 (s, H8), 8.28 (s, H2), 6.07 (d, J = 4.95 Hz, H1’), 4.67 
(t, J = 4.68 Hz, H4’), 4.61-4.50 (m, H5’, H5”), 4.41 (t, J = 5.85 Hz, H3’), 4.31 (t, J = 3.48 
Hz, H2’), 3.71 (d, J = 3.66 Hz, Hα), 3.36 (s, 3H), 3.33 (s, 3H), 3.17-3.11 (m, Hβ), 2.01 
(hextet, J = 6.75 Hz, Hγ), 0.99 (d, J = 6.60 Hz, 3H), 0.89 (d, J = 6.51 Hz, 3H). 
 
4.2.22. ((3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2-iminohexahydrofuro[3,4-
d]oxazol-4-yl)methyl ((2S,3R)-2,3-dihydroxy-4-methylpentanoyl)sulfamate (44) 
1H NMR (500 MHz, CD3OD): δ 8.71 (s, 1H, Ar, 8H), 8.58 (s, 1H, Ar, 2H), 6.34 (s, 1H, 
CH, 1’H), 4.47 (t, 1H, CH, 2’H), 4.43 (d, 1H, CH, 3’H), 4.28 (d, 1H, CH, 4’H), 4.23 (m, 
1H, CH2, 5’H), 4.07 (s, 1H, CH), 3.48 (s, 1H, CH), 1.85 (m, 1H, CH), 0.98 (dd, 6H, CH3); 
MS (FAB) m/z 502 (M+H). 
IV. Part 3. Discovery of Simplified Leucyladenylate Sulfamates 
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as a Novel LRS-targeted mTORC1 Inhibitors 
 
1. Design background & strategy 
In our continuing effort to develop LRS-targeted mTORC1 inhibitors as a potential anti-
cancer agent, we decided to design new scaffolds based on the structures of 
leucyladenylate sulfamate analogues from our previous study.43 Although 
leucyladenylate sulfamate analogues demonstrated highly potent and selective 
cytotoxicity against human colon cancer cells, high polarity of these compounds may 
hinder further pre-clinical development due to synthetic difficulties and poor 
bioavailability. We devised a simplified scaffold by introducing a benzenesulfonamide 
group that replaces 5-O-sulfamoylribose as shown in Figure 27. In this new scaffold, we 
also replaced the adenine group with 3,4-dimethoxyphenyl (2a) or 2-phenoxy (2b) groups 
that were chosen based on a simple immunoblot-based screening of a commercial 
chemical library with approximately 400 compounds. Additionally, we synthesized 
constrained analogues by introducing a cyclic urea group that connects R2 and the amide 
nitrogen, based on our previous finding that a leucinol analogue that contained a cyclic 
urea, (S)-4-isobutyloxazolidin-2-one, demonstrated the most potent inhibition of 
mTORC1.25  
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Figure 27. Leucyladenylate sulfamate (1) and its simplified surrogates. 
 
2. Result and Discussion 
2.1. Chemistry 
3,4-Dimethoxybenzyl analogues (16, 18, 20) were synthesized by following the pathway 
described in Scheme 20. Commercially available 4-nitrobenzenesulfonyl chloride (3) and 
3,4-dimethoxybenzylamine (4) were reacted to give the sulfonamide 5, which was 
subsequently reduced to afford the aniline intermediate 6. Compound 6 was then 
condensed with N-Cbz leucine, O-diacetyl protected (2S,3R)-dihydroxy-4-
methylpentanoic acid (DMPA) or O-acetyl protected (2S)-hydroxyisocaproic acid (HICA, 
L-leucic acid) to yield compounds 7-9, respectively. The acetyl protected DMPA and 
HICA used for these reactions were prepared from commercially available 4-methyl-2-
pentenoic acid and L-leucic acid respectively, by following previously reported 
procedures.36 Deprotection of the α-amino or α-hydroxyl group of compounds 7-9 
provided the final compounds 16, 18, and 20. 
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Scheme 20. Synthesis of 3,4-dimethoxybenzyl analogues.  
Reagents & conditions: (a) TEA, MC, 0 oC to r.t, 2 h; (b) Pd/C, H2, MeOH, r.t, 2 h; (c) i) 
N-Cbz leucine, cyanuric chloride, TEA, acetone for 7, (COCl)2, anhyd. DMF, MC, O-
diacetyl protected chiral acid for 8 and O-acetyl protected L-leucic acid for 9, 0 oC to r.t, 
2 h, ii) 6, DIPEA, anhyd. DMF, 0 oC to r.t, 2 h; (d) Pd/C, H2, 2N NH3 in MeOH, r.t, 
overnight for 16, 0.02M NaOMe, r.t, 2 h for 18 and 20. 
 
Syntheses of phenoxyethyl analogues (17, 19, 21) began with coupling commercially 
available 4-nitrobenzenesulfonyl chloride (3) and 2-phenoxyethylamine (10) as shown in 
Scheme 21. Compounds 11-15, 17, 19, and 21 were synthesized by following the same 
procedures described in Scheme 20.  
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Scheme 21. Synthesis of phenoxyethyl analogues. 
Reagents & conditions: (a) TEA, MC, 0 oC to r.t, 2 h; (b) Pd/C, H2, MeOH, r.t, 2 h; (c) i) 
N-Cbz leucine, cyanuric chloride, TEA, acetone for 13, (COCl)2, anhyd. DMF, MC, O-
diacetyl protected chiral acid for 14 and O-acetyl protected L-leucic acid for 15, 0 oC to 
r.t, 2 h, ii) 12, DIPEA, anhyd. DMF, 0 oC to r.t, 2 h; (d) Pd/C, H2, 2N NH3 in MeOH, r.t, 
overnight for 17, 0.02M NaOMe, r.t, 2 h for 19 and 21. 
 
Cyclic urea analogues of 16 (22 and 26) were synthesized as shown in Scheme 22. 
Carbonylation of 16 by using 1,1’-carbonyldiimidazole (CDI) provided the cyclic urea 
22. Reductive amination of N-Cbz leucinal (23) prepared from N-Cbz leucine, with the 
amine 6 gave compound 24. Subsequent deprotection reaction followed by carbonylation 
with CDI yielded the desired compound 26. 
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Scheme 22. Synthesis of imidazolidin-2-one analogues.  
Reagents & conditions: (a) 1,1’-carbonyldiimidazole, DMF, r.t, 12 h; (b) NaBH3CN, 
AcOH, MeOH, r.t, 12 h; (c) Pd/C, H2, 2N NH3 in MeOH, r.t, overnight. 
 
2.2. Biological Activity 
To evaluate the effect of the synthesized compounds on cellular mTORC1 pathway, we 
first determined leucine-induced phosphorylation of S6Kinase (S6K) in HEK293 cells by 
immunoblots. In our previous studies, we have demonstrated that LRS-targeted inhibitors 
block the phosphorylation of S6K by inhibiting the mTORC1 pathway.25,30 For a primary 
screening, we pretreated HEK293 cells with compounds 16-21 at one fixed concentration 
(200 µM) as well as with compound 1 and rapamycin (100 nM) for comparison, and then 
activated mTORC1 by treating the cells with leucine for 10 min. As shown in Figure 28a, 
leucine induced phosphorylation of S6K, demonstrating an intense band that corresponds 
to pS6K whereas rapamycin and compound 1 inhibited S6K phosphorylation. Among the 
- 76 - 
 
tested compounds, 16 appeared to inhibit S6K phosphorylation to a similar extent as 
compound 1. Based on band intensities of pS6K, compounds 18, 20, and 21 appeared to 
inhibit S6K phosphorylation slightly, while compounds 17 and 19 did not affect 
phosphorylation, suggesting that 3,4-dimethoxybenzyl analogues (16, 18, 20) were more 
potent than the corresponding 2-phenoxyethyl analogues (17, 19, 21). In contrast to our 
previous observation that leucyladenylate sulfamate with an α-hydroxyl group 
(compound 1) demonstrated better inhibition than R2-amino or R1, R2-dihydroxyl 
surrogates,30 compounds with an α-amino group (16 and 17) showed more potent 
inhibition than the α-hydroxyl group containing counter parts (18 and 19), suggesting that 
removing the adenylate may alter the binding interactions. When we examined expression 
levels of S6K, LRS and mTOR, these levels were not affected by the treatment of each 
compound. 
Next, to determine dose-dependent inhibition of S6K phosphorylation, we decided to 
focus on the most potent analogue, compound 16 (Figure 28b). Compound 16 inhibited 
S6K phosphorylation in a dose-dependent manner, showing a significant reduction in 
band intensities starting at 50 µM. Compared to our previous studies requiring 
concentrations greater than 100 µM of compounds to observe a similar degree of 
inhibition, compound 16 appeared to be the most potent among the compounds we have 
developed by far. 
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Figure 28. (a) Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds at fixed concentrations; (b) Dose-dependent inhibition of mTORC1 by 
compound 16. 
 
Next, we evaluated the inhibitory effect of two constrained analogues, 22 and 26, which 
shared the basic scaffold of compound 16, but were further modified based on the 
structure of (S)-4-isobutyloxazolidin-2-one, a cyclic derivative of leucinol.25 To our 
surprise, compound 22 inhibited S6K phosphorylation dose-dependently, even more 
potent than compound 16; however, compound 26 completely lost the inhibitory effect 
(Figure 29). While more detailed SAR studies are needed to explain such a big activity 
difference between 22 and 26, we speculated that the introduction of the conformational 
constraint probably enhanced the inhibitory effect of compound 22. On the contrary, the 
removal of a leucine carbonyl group adversely affected binding interaction of compound 
26, possibly leading to the loss of critical binding interactions with the leucine recognition 
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site of LRS.  
 
 
Figure 29. Dose-dependent inhibition of leucine-induced mTORC1 activation of 
compounds 22 and 26 in HEK293 cells.  
 
To examine whether the inhibitory mechanism of these simplified analogues is related to 
the catalytic activity of LRS, we performed aminoleucylation assays with compounds 16 
and 22. As shown in Figure 30, both compounds showed poor LRS inhibition with the 
IC50 values greater than 800 M, proving that these compounds only acted upon the LRS-
mediated mTORC1 pathway without affecting the canonical function of LRS. Given that 
previously developed leucyladenylate sulfamates have the IC50 values ranging from 22 
nM to 337 nM,30 this result indicates that the replacement of the adenylate group with a 
3,4-dimethoxybenzyl group not only enhanced the inhibitory effect for mTORC1, but 
also improved selectivity.  
- 79 - 
 
 
Figure 30. Inhibition of catalytic leucylation by compounds 16 and 22.  
 
Finally, to evaluate the anticancer activity of 16 and 22, we carried out the sulforhodamine 
B (SRB) colorimetric assays for cytotoxicity.38 A total of six different types of cancer cell 
lines were treated with compounds 16 and 22, in parallel with etoposide as a positive 
control. To determine cancer cell-specific cytotoxicity, normal human lung epithelial cells 
(MRC-5) were also treated with each compound. As shown in Table 2, both compounds 
demonstrated similar IC50 values for all six types of cancer cells while exhibited much 
higher IC50 values for normal MRC-5 cells. Although we did not observe colon cancer-
specific cytotoxicity as demonstrated with compound 1 in our previous study, both 
compounds 16 and 22 showed general cytotoxicity towards various cancer cells without 
exerting significant toxicity on normal cells. Compounds 16 and 22 also appeared to be 
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Table 2. Relative cell growth inhibition of compounds 16 and 22 for various cancer cell 
lines and normal cells. a 
IC50 (μM) A549 HCT116 K562 
MDA-MB-
231 
SK-HEP-1 SNU638 MRC5 
16 5.29 3.96 4.48 5.44 3.07 6.26 > 20 
22 5.54 4.28 2.86 5.65 2.44 5.22 > 20 
Etoposide 0.30 1.06 0.76 1.53 0.63 1.05 11.73 
aA549, lung cancer cells; HCT116, colon cancer cells; K562, leukemia cells; MDA-MB-231, 
breast cancer cells; SK-Hep-1, liver cancer cells; SNU638, stomach cancer cells; MRC5, lung 
normal epithelial cell. 
 
3. Conclusion 
We have developed a new series of LRS-targeted mTORC1 inhibitor based on the 
structures of previously identified inhibitors. In this new series, we replaced the adenylate 
group of leucyladenylate sulfamate (1) with a N-(3,4-
dimethoxybenzyl)benzenesulfonamide group or a N-(2-
phenoxyethyl)benzenesulfonamide group that can maintain specific binding, but has 
more favorable physicochemical properties such as reduced polarity and asymmetric 
centers. 3,4-Dimethoxybenzyl analogues generally showed better inhibition than 2-
phenoxyethyl analogues; additionally, within each series, the presence of an -amino 
group in the R2 position appears to be important for inhibition of the mTORC1 pathway. 
In particular, compound 16 and its constrained analogue 22 effectively inhibited S6K 
phosphorylation in a dose-dependent manner without affecting catalytic leucylation 
activity of LRS. Furthermore, these compounds exhibited cancer cell specific cytotoxicity 
against six different types of cancer cell lines, again supporting that the LRS-mediated 
- 81 - 
 
mTORC1 pathway is a viable target for novel anticancer therapy. Currently, we are 
expanding our library of simplified analogues for in-depth SAR studies to improve 
selectivity and cytotoxicity of LRS-targeted mTORC1 inhibitors. 
 
4. Experimental 
4.1. General Experimental 
All chemical reagents were commercially available. Silica gel column chromatography 
was performed on Silica Gel 60, 230–400 mesh, Merck. Proton NMR spectra were 
recorded on a JEOL JNM-LA 300 at 300 MHz and Bruker Analytik, DE/AVANCE 
Digital 400 at 400 MHz or Bruker AMX-500 (500 MHz) spectrometer. Chemical shifts 
are reported in ppm units with tetramethylsilane as a reference standard. Mass spectra and 
HRMS results were recorded on VG Trio-2 GC−MS instrument and JEOL JMS-AX 
instrument, respectively. 
 
4.2. General procedure 
4.2.1. Sulfonamide synthesis (Procedure A). 
A solution of 3,4-dimethoxybenzylamine 4 or 2-phenoxyethylamine 10 (1.2 equiv.) in 
MC was cooled to 0oC and triethylamine (2.4 equiv.) was added. The resulting solution 
was stirred for 10 min and 4-nitrobenzenesulfonyl chloride 3 (1 equiv.) was added to the 
mixture and then stirred for 2 h at room temperature. The reaction was quenched with 
water and extracted with EtOAc twice. The combined organic extracts were dried over 
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MgSO4, filtered, and evaporated in vacuo. The residue was purified by column 
chromatography over silica gel to afford the corresponding sulfonamide product. 
 
4.2.2. Nitro reduction (Procedure B). 
A solution of 4-nitrobenzensulfonamide derivatives in methanol was added 10% Pd/C 
catalyst (0.1 mg/1 mg) and stirred under hydrogen gas in balloon for 2 h at room 
temperature. After completed, the reaction mixture was filtered on celite pad, evaporated 
in vacuo. The residue was purified by column chromatography over silica gel to afford 
the corresponding aniline product. 
 
4.2.3. Amide coupling (Procedure C). 
Method A: a solution of N-Cbz leucine (3 equiv.) in acetone was cooled to 0oC and 
cyanuric chloride (3 equiv.) followed by triethylamine (6 equiv.) was added. The reaction 
mixture was stirred for 2 h at room temperature. After in situ generation of acyl chloride 
completed, the solvent was evaporated and the mixture was dissolved in DMF. Aniline (1 
equiv.) and DIPEA (3 equiv.) were added at 0oC and the reaction mixture was stirred for 
2 h at room temperature. The reaction was quenched with aqueous NH4Cl and extracted 
with EtOAc twice. The combined organic extracts were dried over MgSO4, filtered, and 
evaporated in vacuo. The residue was purified by column chromatography over silica gel 
to afford the corresponding amide product. 
 
Method B: a solution of carboxylic acid (DMPA or HICA, 3 equiv.) in anhydrous MC 
was cooled to 0oC and oxalyl chloride (3.6 equiv.) followed by anhyd. DMF (cat.) was 
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added. The reaction mixture was stirred for 2 h at room temperature. After in situ 
generation of acyl chloride completed, the solvent was evaporated and the mixture was 
dissolved in DMF. Aniline (1 equiv.) and DIPEA (3 equiv.) were added at 0oC and the 
reaction mixture was stirred for 2 h at room temperature. The reaction was quenched with 
aqueous NH4Cl and extracted with EtOAc twice. The combined organic extracts were 
dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by column 
chromatography over silica gel to afford the corresponding amide product. 
 
4.2.4. Cbz deprotection (Procedure D).  
A solution of starting material in 2N NH3 in methanol was added 10% Pd/C catalyst (0.1 
mg/1 mg) and stirred under hydrogen gas in balloon for overnight at room temperature. 
After completed, the reaction mixture was filtered on celite pad, evaporated in vacuo. The 
residue was purified by column chromatography over silica gel to afford the 
corresponding final compound. 
 
4.2.5. Acetyl deprotection (Procedure E). 
The starting material was dissolved in 0.02 M sodium methoxide solution in methanol 
(0.1 ml/1 mg) and stirred for 2 h at room temperature. DOWEX 50WX8 hydrogen form 
resin was added in portions to adjust the pH 7, filtered and concentrated to afford the 
corresponding final compound. 
 
4.2.6. CDI coupling (Procedure F). 
A solution of diamine (1 equiv.) in DMF was added 1,1’-carbonyldiimidazole (1.1 equiv.) 
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at room temperature and stirred for 12 h. The reaction was quenched with water and 
extracted with EtOAc twice. The combined organic extracts were dried over MgSO4, 
filtered, and evaporated in vacuo. The residue was purified by column chromatography 
over silica gel to afford the corresponding cyclic urea product. 
 
4.2.7. Reductive amination (Procedure G). 
To a mixture of aldehyde (1 equiv.) and aniline (1 equiv.) in methanol was added acetic 
acid (1 equiv.) followed by NaBH3CN (5 equiv.) and the reaction mixture was stirred for 
12 h at room temperature. The reaction was quenched with aqueous NaHCO3 and 
extracted with EtOAc twice. The combined organic extracts were dried over MgSO4, 
filtered, and evaporated in vacuo. The residue was purified by column chromatography 
over silica gel to afford the corresponding product. 
 
4.3. Chemical spectra 
4.3.1. N-(3,4-Dimethoxybenzyl)-4-nitrobenzenesulfonamide (5). 
Compound 5 was synthesized by following the general procedure A. Yield 90%, white 
solid; 1H-NMR (300 MHz, CDCl3)  8.31 (d, 2H, J = 8.27 Hz), 7.99 (d, 2H, J = 8.27 Hz), 
6.64-6.72 (m, 3H), 4.91 (m, 1H), 4.13 (m, 2H), 3.81 (s, 3H), 3.79 (s, 3H); MS (ESI) m/z 
353 [M+H]+. 
 
4.3.2. 4-Amino-N-(3,4-dimethoxybenzyl)benzenesulfonamide (6). 
Compound 6 was synthesized by following the general procedure B. Yield 97%, yellow 
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solid; 1H-NMR (300 MHz, CD3OD)  7.50 (m, 2H), 6.63-6.82 (m, 5H), 3.93 (s, 2H), 3.77 
(s, 3H), 3.74 (s, 3H); MS (ESI) m/z 323 [M+H]+.  
4.3.3. Benzyl (S)-(1-((4-(N-(3,4-dimethoxybenzyl)sulfamoyl)phenyl)amino)-4-
methyl-1-oxopentan-2-yl)carbamate (7). 
Compound 7 was synthesized by following the general procedure C (method A). Yield 
76%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.62 (s, 4H), 7.21-7.26 (m, 5H), 6.61-
6.70 (m, 3H), 5.00 (s, 2H), 4.19 (m, 1H), 3.91 (s, 2H), 3.65 (s, 3H), 3.61 (s, 3H), 1.62 (m, 
1H), 1.53 (m, 2H), 0.89 (m, 6H); MS (ESI) m/z 570 [M+H]+. 
 
4.3.4. (S)-1-((4-(N-(3,4-Dimethoxybenzyl)sulfamoyl)phenyl)amino)-4-methyl-1-
oxopentan-2-yl acetate (8). 
Compound 8 was synthesized by following the general procedure C (method B). Yield 
62%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.72 (d, 2H, J = 8.61 Hz), 7.59 (d, 
2H, J = 8.79 Hz), 6.67 (m, 3H), 4.71 (t, 1H, J = 6.03 Hz), 3.98 (t, 1H, J = 6.03 Hz), 3.77 
(s, 3H), 3.74 (s, 3H), 2.16 (s, 3H), 1.79 (m, 1H), 1.70 (m, 2H), 0.90 (t, 1H, J = 6.03 Hz); 
MS (ESI) m/z 479 [M+H]+. 
 
4.3.5. (2S,3R)-1-((4-(N-(3,4-Dimethoxybenzyl)sulfamoyl)phenyl)amino)-4-methyl-1-
oxopentane-2,3-diyl diacetate (9). 
Compound 9 was synthesized by following the general procedure C (method B). Yield 
55%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.73 (d, 2H, J = 8.97 Hz), 7.65 (d, 
2H, J = 8.97 Hz), 6.69-6.80 (m, 3H), 5.27 (d, 1H, J = 2.86 Hz), 5.17 (dd, 1H, J = 8.8, 3.1 
Hz), 4.01 (s, 2H), 3.76 (s, 3H), 3.70 (s, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 2.03 (m, 1H), 0.98 
- 86 - 
 
(dd, 6H, J = 9.72, 6.78 Hz); MS (FAB) m/z 559 [M+Na]+. 
 
4.3.6. 4-Nitro-N-(2-phenoxyethyl)benzenesulfonamide (11). 
Compound 11 was synthesized by following the general procedure A. Yield 96%, white 
solid; 1H-NMR (300 MHz, CD3OD)  8.25 (d, 2H, J = 8.97 Hz), 7.99 (d, 2H, J = 8.97 
Hz), 7.18 (t, 3H, J = 7.32 Hz), 6.90 (d, 1H, J = 7.53 Hz), 6.69 (d, 2H, J = 7.68 Hz), 5.10 
(t, 1H, J = 6.03 Hz), 3.93 (t, 2H, J = 4.77 Hz), 3.39 (q, 2H, J = 5.49 Hz); MS (ESI) m/z 
323 [M+H]+. 
 
4.3.7. 4-Amino-N-(2-phenoxyethyl)benzenesulfonamide (12). 
Compound 12 was synthesized by following the general procedure B. Yield 89%, yellow 
solid; 1H-NMR (300 MHz, CD3OD)  7.41-7.47 (m, 2H), 7.09-7.16 (m, 2H), 6.73-6.83 
(m, 3H), 6.54-6.61 (m, 2H), 3.84 (t, 2H, J = 5.71 Hz), 3.09 (t, 2H, J = 5.71 Hz); MS (ESI) 




Compound 13 was synthesized by following the general procedure C (method A). Yield 
87%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.67-7.81 (m, 4H), 7.27.-7.37 (m, 4H), 
7.16-7.23 (m, 3H), 6.89 (m, 1H), 6.78 (d, 2H, J = 7.89 Hz), 5.09 (s, 2H), 4.31 (m, 1H), 
3.92 (t, 2H, J = 5.5 Hz), 3.26 (t, 2H, J = 5.55 Hz), 1.53-1.74 (m, 3H), 0.97 (dd, 6H, J = 
6.47, 2.62 Hz); MS (FAB) m/z 562 [M+H]+.  
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4.3.9. (S)-4-Methyl-1-oxo-1-((4-(N-(2-
phenoxyethyl)sulfamoyl)phenyl)amino)pentan-2-yl acetate (14). 
Compound 14 was synthesized by following the general procedure C (method B). Yield 
65%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.72 (d, 2H, J = 8.97 Hz), 7.64 (d, 
2H, J = 8.97 Hz), 7.10 (t, 2H, J = 7.50 Hz), 6.78 (t, 2H, J = 7.50 Hz), 6.68 (d, 1H, J = 
8.79 Hz), 4.97 (dd, 1H, J = 9.51, 3.84 Hz), 3.82 (t, 2H, J = 5.49 Hz), 3.17 (t, 2H, J = 5.49 
Hz), 2.05 (s, 3H), 1.72 (m, 2H), 1.53 (m, 1H), 0.89 (dd, 6H, J = 6.42, 4.95 Hz); MS (ESI) 
m/z 449 [M+H]+. 
 
4.3.10. (2S,3R)-4-Methyl-1-oxo-1-((4-(N-(2-
phenoxyethyl)sulfamoyl)phenyl)amino)pentane-2,3-diyl diacetate (15). 
Compound 15 was synthesized by following the general procedure C (method B). Yield 
72%, colorless oil; 1H-NMR (300 MHz, CD3OD)  7.81 (d, 2H, J = 8.79 Hz), 7.67 (d, 
2H, J = 8.79 Hz), 7.21 (t, 2H, J = 8.61 Hz), 6.88 (t, 2H, J = 7.32 Hz), 6.79 (d, 1H, J = 
7.68 Hz), 5.28 (d, 1H, J = 2.94 Hz), 5.17 (dd, 1H, J = 8.79, 2.76 Hz), 3.93 (t, 2H, J = 5.52 
Hz), 3.26 (t, 2H, J = 5.49 Hz), 2.06 (m, 1H), 0.98 (dd, 6H, J = 9.9, 6.78 Hz); MS (ESI) 




Compound 16 was synthesized by following the general procedure D. Yield 88%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.64 (m, 4H), 6.66 (m, 3H), 3.92 (s, 2H), 3.66 (s, 
3H), 3.62 (s, 3H), 3.60 (m, 1H), 1.44-1.70 (m, 3H), 0.90 (dd, 6H, J = 6.39, 3.66 Hz); 
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Compound 17 was synthesized by following the general procedure D. Yield 94%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.70 (m, 4H), 7.11 (m, 2H), 6.79 (t, 1H, J = 7.50 
Hz), 6.70 (m, 2H), 3.83 (t, 2H, J = 5.49 Hz), 3.39 (dd, 1H, J = 8.20, 6.03 Hz), 3.16 (t, 2H, 
J = 5.50 Hz), 1.33-1.72 (m, 3H), 0.88 (t, 6H, J = 5.50 Hz); HRMS (FAB) calcd for 




Compound 18 was synthesized by following the general procedure E. Yield 85%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.69 (m, 4H), 6.68 (m, 3H), 4.09 (t, 1H, J = 6.78 
Hz), 3.91 (s, 2H), 3.67 (s, 3H), 3.62 (s, 3H), 1.83 (m, 1H), 1.51 (m, 2H), 0.90 (d, 3H, J = 





Compound 19 was synthesized by following the general procedure E. Yield 88%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.71 (m, 4H), 7.11 (t, 2H, J = 8.58 Hz), 6.79 (t, 2H, 
J = 7.50 Hz), 6.71 (t, 2H, J = 8.61 Hz), 4.09 (t, 1H, J = 7.14 Hz), 3.84 (t, 2H, J = 5.52 
- 89 - 
 
Hz), 3.16 (t, 2H, J = 5.52 Hz), 1.80 (m, 1H), 1.51 (m, 2H), 0.89 (dd, 6H, J = 6.60, 2.19 




Compound 20 was synthesized by following the general procedure E. Yield 80%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.77 (m, 4H), 6.78 (s, 1H), 6.72 (m, 2H), 4.25 (d, 
1H, J = 1.81 Hz), 4.00 (s, 2H), 3.76 (s, 3H), 2,92 (s, 3H), 3.52 (dd, 1H, J = 8.97, 1.83 Hz), 
1.89-2.01 (m, 1H), 1.02 (dd, 6H, J = 6.80, 3.40 Hz); HRMS (FAB) calcd for 




Compound 21 was synthesized by following the general procedure E. Yield 94%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.82 (m, 4H), 7.21 (t, 2H, J = 7.32 Hz), 6.90 (t, 
2H, J = 7.32 Hz), 6.81 (d, 1H, J = 7.89 Hz), 4.25 (d, 1H, J = 1.83 Hz), 3.93 (t, 2H, J = 
5.49 Hz), 3.52 (dd, 1H, J = 9.15, 1.83 Hz), 3.25 (t, 2H, J = 5.49 Hz), 1.91 (m, 1H), 1.04 
(d, 1H, J = 6.57 Hz), 0.98 (d, 1H, J = 6.78 Hz) ; HRMS (FAB) calcd for C22H29N2O7S+ 




Compound 22 was synthesized by following the general procedure F. Yield 69%, white 
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solid; 1H-NMR (300 MHz, CD3OD)  7.88 (d, 2H, J = 8.97 Hz), 7.50 (d, 2H, J = 8.79 
Hz), 6.69-6.80 (m, 3H), 4.28 (m, 1H), 4.04 (s, 2H), 3.76 (s, 3H), 3.71 (s, 3H), 1.61-1.95 
(m, 3H), 1.01 (d, 6H, J = 6.42 Hz); HRMS (FAB) calcd for C28H32N3NaO7S2+ [M+Na]+: 
578.1859, found: 578.1909. 
 
4.3.18. Benzyl (S)-(4-methyl-1-oxopentan-2-yl)carbamate (23). 
Compound 23 was synthesized by following the reported procedures.44 Yield 60% in 
three steps, yellow solid; 1H-NMR (300 MHz, CDCl3)  9.58 (s, 1H), 7.30-7.36 (m, 5H), 
5.15 (m, 1H), 5.10 (s, 2H), 4.33 (m, 1H), 1.63-1.80 (m, 2H), 1.35-1.44 (m, 1H), 0.95 (m, 




Compound 24 was synthesized by following the general procedure G. Yield 59%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.52 (m, 2H), 7.31-7.32 (m, 5H), 6.64-6.81 (m, 
5H), 5.05 (d, 2H, J = 3.14 Hz) 3.92 (s, 2H), 3.87 (m, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.17 
(m, 2H), 1.70 (m, 1H), 1.28-1.44 (m, 2H), 0.91 (dd, 6H, J = 14.52, 6.78 Hz); MS (FAB) 




Compound 25 was synthesized by following the general procedure D. Yield 92%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.52 (m, 2H), 6.62-6.82 (m, 5H), 3.94 (s, 2H), 3.77 
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(s, 3H), 3.73 (s, 3H), 3.72 (m, 1H), 2.98-3.01 (m, 2H), 1.82 (m, 1H), 1.28-1.34 (m, 2H), 




Compound 26 was synthesized by following the general procedure F. Yield 51%, white 
solid; 1H-NMR (300 MHz, CD3OD)  7.68 (m, 4H), 6.77 (s, 1H), 6.73 (d, 1H, J = 1.83 
Hz), 6.69 (m, 1H), 4.08 (t, 1H, J = 8.79 Hz), 4.00 (s, 2H), 3.92 (m, 1H), 3.77 (s, 3H), 3.71 
(s, 3H), 3.53 (dd, 1H, J = 9.15, 6.42 Hz), 1.78 (m, 1H), 1.43-1.62 (m, 2H), 0.99 (d, 6H, J 
= 6.60 Hz); HRMS (FAB) calcd for C22H30N3O5S+ [M+H]+: 448.1828, found: 448.1871. 
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V. Part 4. Discovery of New Series of Simplified 
Leucyladenylate Sulfamates as a Novel LRS-targeted 
mTORC1 Inhibitors 
 
1. Design background & strategy 
Our group currently reported that (S)-2-hydroxy-4-methylpentanoyl adenylate sulfamate 
(1) as a potent mTORC1 inhibitor, which possesses selective anti-cancer activity against 
human colorectal cancer cells in which mTORC1 is hyperactive.30 Furthermore, we 
discovered simplified leucyladenylate structures that can maintain the inhibitory activity 
of mTORC1 but also have more improved physicochemical properties to further develop 
as a pre-clinical candidate.43  
 
 
Figure 31. (S)-2-hydroxy-4-methylpentanoyl adenylate sulfamate (1) and gefitinib (2). 
 
In our continuing efforts to develop LRS-targeted mTORC1 inhibitors as a potential anti-
cancer agent and further expand our in-house library of simplified leucyladenylates 
analogues, we decided to design new scaffolds based on the gefitinib structure (Figure. 
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31). We devised new series of simplified structures by introducing N-(3-chloro-4-
fluorophenyl) quinazolin-4-amine instead of adenine group and various linker structures 
to replace 5-O-sulfamoylribose (Figure. 32). 
 
 
Figure 32. New simplified adenylates in conjunction with gefitinib structure. 
 
2. Result and Discussion 
2.1. Chemistry 
Synthesis of intermediates (4, 5, 6 and 8) began with compound 3, which was prepared 
by following the reported procedures (scheme 23).45 To synthesize the intermediate 4, 
compound 3 was reacted with sulfamoyl chloride prepared in a quantitative yield from 
chlorosulfonyl isocyanate according to previously reported procedures.35 Ethyl alcohol 




























X = NH2, OH
Y = NH, OH
R
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subsequently sulfamoylated to give intermediate 6. O-alkylation of compound 3 with 1,2-
dibromoethane gave compound 7, which was then reacted with aqueous ammonia 
solution to produce primary amino group. 
 
 
Scheme 23. Synthesis of intermediates from compound 3. 
Reagents & conditions: (a) Sulfamoyl chloride, DMA, 0 
o
C to r.t, overnight; (b) 2-
Bromoethanol, K2CO3, DMF, r.t, 12 h; (c) 1,2-Dibromoethane, K2CO3, DMF, r.t, 12 h; (d) 
NH4OH, DMF, 50
 o
C, 24 h. 
 
Synthesis of compounds without ethyl linker in simplified adenylate structure (11, 12, 15 
and 16) were carried out as illustrated in Scheme 24. Compound 3 was coupled with N-
Cbz leucine and O-benzyl protected (2S)-hydroxyisocaproic acid (HICA, l-leucic acid) to 
afford compounds 9 and 10, respectively. Also, intermediate 4 was condensed with N-
Cbz leucine and O-acetyl protected HICA to give compounds 13 and 14, respectively. O-
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benzyl or O-acetyl protected HICA were prepared by benzylation or acetylation of 
commercially available L-leucic acid. Deprotection of the -amino or -hydroxyl group 




Scheme 24. Synthesis of simplified leucyladenylate sulfamates analogues without ethyl 
linker. 
Reagents & conditions: (a) Cyanuric chloride, TEA, Acetone, N-Cbz leucine for 9, O-
benzyl protected L-leucic acid for 10, 0 
o
C to r.t, 2 h; (b) Pd/C, H2, 2M NH3 in MeOH, r.t, 
overnight for 11, BBr3, MC, -78 
o
C to r.t, 12 h for 12; (c) DCC, DMAP, anhyd. MC, N-
Cbz leucine for 13, O-acetyl protected L-leucic acid for 14, r.t, 2 h; (d) Pd/C, H2, 2M NH3 
in MeOH, r.t, overnight for 15, 0.02M NaOMe, 0 
o
C to r.t, 2 h for 16. 
 
Compounds containing ethyl linker in simplified adenylate structure (21-24, 27 and 28) 
were synthesized as shown in scheme 25. Compounds 17-28 were synthesized by 
following the same procedures described in scheme 24. 




Scheme 25. Synthesis of simplified leucyladenylate sulfamates analogues with ethyl 
linker. 
Reagents & conditions: (a) Cyanuric chloride, TEA, Acetone, N-Cbz leucine for 17 and 
19, O-acetyl protected L-leucic acid for 18 and 20, 0 
o
C to r.t, 2 h; (b) Pd/C, H2, 2M NH3 
in MeOH, r.t, overnight for 21 and 23, 0.02M NaOMe, 0 
o
C to r.t, 2 h for 22 and 24; (c) 
DCC, DMAP, anhyd. MC, N-Cbz leucine for 25, O-acetyl protected L-leucic acid for 26, 
r.t, 2 h; (d) Pd/C, H2, 2M NH3 in MeOH, r.t, overnight for 27, 0.02M NaOMe, 0 
o
C to r.t, 
2 h for 28. 
 
2.2. Biological Activity 
First, we examined the effects of synthesized compounds on cellular mTORC1 activation 
pathway by leucine-induced phosphorylation of S6Kinase (S6K) by immunoblotting 
method. In our previous studies, we have discovered that LRS-targeted inhibitors block 
the phosphorylation of S6K by inhibiting the mTORC1 pathway.25,30,43 As a primary 
screening, we pretreated HEK293 cells with each final compounds at one fixed 
concentration (200 M) as well as with rapamycin (100 nM) and leucinol (800 M) as a 
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comparison, and then activated mTORC1 by treating the cells with leucine for 10 min. 
As shown in Figure. 33, pretreatment of rapamycin and leucinol blocked leucine-induced 
phosphorylation of S6K according to a weak pS6K band intensity. Among the 
synthesized compounds, 16, 21, 22 and 23 showed more potent inhibition of S6K 
phosphorylation than leucinol, while compounds 11, 12, 27 and 28 did not inhibit S6K 
phosphorylation, suggesting that the distance between the leucyl side chain and adenylate 
binding site is critical to activity. Compounds which showed mTORC1 inhibition (16, 21, 
22 and 23) have sulfonamide, ethyl alcohol or ethyl amino linker in simplified adenylate 
structure. Specifically, in the case of compounds with sulfonamide linker, compound 
which has α-hydroxyl group (16) showed more potent inhibition than the α-amino group 
containing counterpart (15). However, in the case of compounds with ethyl amino linker, 
compound with α-amino group (23) showed more potent inhibition than the compound 
with α-hydroxyl group (24), suggesting that the binding interactions may change 
depending on the liker structures. 
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Figure 33. Inhibition of leucine-induced mTORC1 activation in HEK293 cells treated 
with compounds at fixed concentrations.  
 
Next, we examined the dose-dependent inhibition of mTORC1 with compounds 16, 21, 
22 and 23 based on the primary screening (Figure. 34). Interestingly, only compounds 
16 and 22 appeared to inhibit S6K phosphorylation in a dose-dependent manner. 
Compounds 16, 21 and 22 started to inhibit S6K phosphorylation strongly at 100 M, 
showing a significant reduction in pS6K band intensities, but compound 23 did not inhibit 
S6K phosphorylation at the same concentration. When we examined expression level of 
pmTOR, the band intensities were not affected by the compounds, suggesting that these 
compounds were LRS-targeted mTORC1 inhibitors. 
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Figure 34. Dose-dependent inhibition of leucine-induced mTORC1 activation of 
compounds 16, 21, 22 and 23 in HEK293 cells.  
 
To further investigate the inhibitory mechanism whether these simplified analogues affect 
catalytic activity of LRS or not, we performed aminoleucylation assays with compounds 
16, 21, 22 and 23. As shown in Figure. 35, all tested compounds did not inhibit catalytic 
function of LRS even at micromole range of concentration, indicating that these 
compounds selectively acted on LRS-mediated mTORC1 activation pathway without 
direct effect on catalytic activity of LRS. This result suggests that these simplified 
adenylate analogues selectively bind to LRS to inhibit mTORC1 pathway, which is in 
agreement with our previous report.43 
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Figure 35. Inhibition of catalytic leucylation by compounds 16, 21, 22 and 23. 
 
Finally, to assess the anticancer activity of 16, 21, 22 and 23, we performed the 
sulforhodamine B (SRB) colorimetric assays for cytotoxicity.38 Compounds 16, 21, 22 
and 23 were treated with six different types of cancer cell lines along with etoposide as a 
positive control. As shown in Table 3, all compounds showed moderate cytotoxicity with 
low micromole range against various cancer cell lines compared with etoposide. 
 




IC50 (μM) A549 HCT116 K562 MDA-MB-231 SK-HEP-1 SNU638 
16 4.38 4.04 4.10 6.23 3.30 4.94 
21 3.59 3.97 4.01 3.65 1.94 3.86 
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22 3.16 3.12 3.89 2.05 1.39 3.41 
23 2.79 4.24 3.83 4.59 2.21 2.97 
Etoposide 0.30 1.06 0.76 1.53 0.63 1.05 
aA549, lung cancer cells; HCT116, colon cancer cells; K562, leukemia cells; MDA-MB-231, 
breast cancer cells; SK-Hep-1, liver cancer cells; SNU638, stomach cancer cells; MRC5, lung 
normal epithelial cell. 
 
3. Conclusion 
We have developed a new series of simplified leucyladenylate sulfamate analogues that 
can directly bind to LRS to inhibit mTORC1 activation pathway. In this new series, we 
introduced N-(3-chloro-4-fluorophenyl) quinazolin-4-amine to replace the adenine group 
and various linker structures to replace 5-O-sulfamoylribose group that can maintain the 
activity but also improve the druggable physicochemical properties such as reduced 
polarity and asymmetric centers. Compounds with sulfonamide, ethyl alcohol or ethyl 
amino linker in simplified adenylate structure (16, 21, 22 and 23) showed potent 
inhibition than compounds with the no linker or sulfamoylated ethyl alcohol linker 
without affecting the catalytic activity of LRS. Furthermore, these compounds showed 
general cytotoxicity against various types of cancer cell lines, suggesting that they have 
a potential as effective anticancer agent. 
 
4. Experimental 
4.1. General Experimental 
All chemical reagents were commercially available. Silica gel column chromatography 
was performed on Silica Gel 60, 230–400 mesh, Merck. Proton NMR spectra were 
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recorded on a JEOL JNM-LA 300 at 300 MHz and Bruker Analytik, DE/AVANCE 
Digital 400 at 400 MHz or Bruker AMX-500 (500 MHz) spectrometer. Chemical shifts 
are reported in ppm units with tetramethylsilane as a reference standard. Mass spectra and 
HRMS results were recorded on VG Trio-2 GC−MS instrument and JEOL JMS-AX 
instrument, respectively. 
 
4.2. General procedure 
4.2.1. Sulfamoylation (Procedure A) 
To a solution of starting material in DMA (6 ml) was added freshly prepared sulfamoyl 
chloride (1.5 equiv.) at 0oC and gradually increased to room temperature. The reaction 
mixture was stirred for overnight until the starting material disappeared and quenched 
with MeOH (6 ml) at 0oC. The reaction mixture evaporated and purified by silica gel flash 
column chromatography to afford the corresponding sulfamoylated product. 
 
4.2.2. O-alkylation (Procedure B) 
To a solution of starting material in DMF (6 ml) was added K2CO3 (3 equiv.) followed by 
2-bromoethanol (3 equiv.) or 1,2-dibromoethane (3 equiv.). The reaction mixture was 
stirred at room temperature for 12 h and quenched with water (10 ml). The mixture was 
extracted with ethyl acetate (2 x 50 ml), washed with brine (3 x 50 ml), dried over MgSO4 
and evaporated. The residue was purified by silica gel flash column chromatography to 
afford the corresponding O-alkylated product. 
- 103 - 
 
 
4.3. Procedures and Chemical spectra 
4.3.1. 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl sulfamate (4) 
Compound 4 was prepared by following the general procedure A. Yield 75%, white solid; 
1H-NMR (300 MHz, DMSO)  8.88 (s, 1H), 8.56 (s, 1H), 7.95 (dd, 1H, J = 6.78, 2.22 




Compound 5 was prepared by following the general procedure B. Yield 30%, white solid; 
1H-NMR (300 MHz, CD3OD)  8.42 (s, 1H), 8.04 (dd, 1H, J = 6.60, 2.58 Hz), 7.74 (s, 
1H), 7.69-7.63 (m, 1H), 7.25 (t, 1H, J = 8.97 Hz), 7.18 (s, 1H), 4.48 (t, 1H, J = 6.06 Hz), 




Compound 6 was prepared by following the general procedure A. Yield 75%, white solid; 
1H-NMR (300 MHz, CD3OD)  8.36 (s, 1H), 7.91 (dd, 1H, J = 6.57, 2.55 Hz), 7.65 (s, 
1H), 7.60-7.56 (m, 1H), 7.16 (t, 1H, J = 8.97 Hz), 7.09 (s, 1H), 4.49-4.46 (m, 2H), 4.38-
4.35 (m, 2H), 3.91 (s, 3H). 





Compound 7 was prepared by following the general procedure B. Yield 45%, white solid; 
1H-NMR (300 MHz, CD3OD)  8.44 (s, 1H), 8.00 (dd, 1H, J = 6.60, 2.58 Hz), 7.74 (s, 
1H), 7.69-7.63 (m, 1H), 7.25 (t, 1H, J = 8.97 Hz), 7.18 (s, 1H), 4.50 (t, 1H, J = 6.06 Hz), 




To a solution of compound 7 in DMF (6 ml) was added NH4OH (excess amount) at room 
temperature and gradually increased to 50oC. The reaction mixture was stirred for 24 h 
until the starting material disappeared and DMF was removed under reduced pressure to 
afford the primary amine. The crude product was directly used to next reaction. Yield 
94%, yellow oil; 1H-NMR (300 MHz, CD3OD)  8.41 (s, 1H), 8.14 (s, 1H), 8.01-7.99 (m, 





Compound 9 was prepared by following the procedure in previous report.43 Yield 32%, 
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white solid; 1H-NMR (300 MHz, CD3OD)  8.51 (s, 1H), 8.03 (s, 1H), 8.01 (m, 1H), 
7.66-7.63 (m, 1H), 7.37-7.20 (m, 7H), 5.14 (s, 2H), 4.55 (m, 1H), 3.92 (s, 3H), 1.85 (m, 




Compound 10 was prepared by following the procedure in previous report.43 Yield 58%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.54 (s, 1H), 8.17 (s, 1H), 8.02 (m, 1H), 
7.70-7.65 (m, 1H), 7.41-7.22 (m, 7H), 4.55 (d, 1H, J = 11.70 Hz), 4.33 (m, 1H), 4.01 (s, 
3H), 1.88 (m, 1H), 1.23 (t, 1H, J = 7.14 Hz), 0.99 (d, 3H, J = 6.42 Hz), 0.91 (d, 3H, J = 
6.39 Hz). 
 
4.3.8. 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl L-leucinate (11) 
Compound 11 was prepared by following the procedure in previous report.43 Yield 58%, 
white solid; 1H-NMR (300 MHz, DMSO)  9.68 (s, 2H), 9.47 (s, 1H), 8.46 (s, 1H), 8.20 
(dd, 1H, J = 6.78, 2.58 Hz), 7.83 (m, 1H), 7.77 (s, 1H), 7.40 (t, 1H, J = 8.97 Hz), 7.20 (s, 
1H), 3.96 (s, 3H), 3.60 (m, 1H), 1.44 (m, 1H), 1.22 (s, 2H), 0.89-0.82 (m, 6H); MS (FAB) 
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BBr3 (1.5 equiv.) was added dropwise to a stirred solution of compound 10 (1 equiv.) in 
CH2Cl2 at -78oC and gradually increased to room temperature. The reaction mixture was 
stirred for 12 h until the starting material disappeared and quenched with MeOH at 0oC. 
The reaction mixture evaporated and purified by silica gel flash column chromatography 
to afford compound 12. Yield 60%, white solid; 1H-NMR (300 MHz, CD3OD)  8.44 (s, 
1H), 8.02 (s, 1H), 7.92 (dd, 1H, J = 6.60, 2.58 Hz), 7.57 (m, 1H), 7.20 (s, 1H), 7.16 (t, 
1H, J = 8.97 Hz), 4.41 (m, 1H), 3.88 (s, 3H), 1.91 (m, 1H), 1.73-1.68 (m, 2H), 0.94 (dd, 




Compound 13 was prepared by following the procedure in previous report.32 Yield 45%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.45 (s, 1H), 8.19 (s, 1H), 7.95 (dd, 1H, J = 
6.78, 2.55 Hz), 7.20 (s, 1H), 7.17-7.13 (m, 6H), 4.90 (d, 2H, J = 4.02 Hz), 4.15-4.08 (m, 
1H), 3.98 (s, 3H), 1.72 (m, 1H), 1.56-1.49 (m, 2H), 0.99 (d, 6H, J = 6.57 Hz). 
 
4.3.11. (S)-1-((((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-
yl)oxy)sulfonyl)amino)-4-methyl-1-oxopentan-2-yl acetate (14) 
Compound 14 was prepared by following the procedure in previous report.32 Yield 49%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.50 (s, 1H), 8.14 (s, 1H), 8.00 (dd, 1H, J = 
6.78, 2.76 Hz), 7.71-7.67 (m, 1H), 7.25 (t, 1H, J = 8.97 Hz), 7.24 (s, 1H), 4.00 (s, 3H), 
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Compound 15 was prepared by following the procedure in previous report.43 Yield 52%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.34 (s, 1H), 7.69-7.64 (m, 3H), 7.16 (s, 1H), 
7.12 (t, 1H, J = 8.61 Hz), 4.04 (s, 3H), 3.98 (dd, 1H, J = 10.44, 3.12 Hz), 1.85-1.75 (m, 




Compound 16 was prepared by following the procedure in previous report.43 Yield 46%, 
white solid; 1H-NMR (300 MHz, DMSO)  9.60 (s, 1H), 9.46 (s, 2H), 8.46 (s, 1H), 8.20 
(dd, 1H, J = 6.78, 2.58 Hz), 7.85-7.79 (m, 1H), 7.76 (s, 1H), 7.40 (t, 1H, J = 9.18 Hz), 
7.20 (s, 1H), 3.96 (s, 3H), 3.15 (d, 1H, J = 4.38 Hz), 1.98 (m, 1H), 1.75-1.55 (m, 2H), 




Compound 17 was prepared by following the procedure in previous report.43 Yield 37%, 
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white solid; 1H-NMR (300 MHz, CD3OD)  8.45 (s, 1H), 8.01 (dd, 1H, J = 6.75, 2.73 
Hz), 7.75 (s, 1H), 7.68 (m, 1H), 7.27-7.16 (m, 7H), 5.03 (s, 2H), 4.60-4.40 (m, 4H), 4.23 
(t, 1H, J = 6.96 Hz), 3.97 (s, 3H), 1.68 (m, 1H), 1.59-1.54 (m, 2H), 0.88 (d, 3H, J = 6.39 




Compound 18 was prepared by following the procedure in previous report.43 Yield 43%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.45 (s, 1H), 8.00 (dd, 1H, J = 6.78, 2.58 
Hz), 7.76 (s, 1H), 7.69-7.64 (m, 1H), 7.25 (t, 1H, J = 8.97 Hz), 7.18 (s, 1H), 5.02-4.95 
(m, 2H), 4.64-4.50 (m, 2H), 4.42 (m, 1H), 4.00 (s, 3H), 2.06 (s, 3H), 1.79-1.57 (m, 3H), 





Compound 19 was prepared by following the procedure in previous report.43 Yield 33%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.46 (s, 1H), 8.05 (dd, 1H, J = 6.78, 2.58 
Hz), 7.79 (s, 1H), 7.68 (m, 1H), 7.28-7.16 (m, 7H), 5.02 (s, 2H), 4.24 (m, 2H), 4.13 (m, 
1H), 3.98 (s, 3H), 3.69 (m, 2H), 1.79-1.57 (m, 3H), 0.91 (t, 6H, J = 6.39 Hz). 
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4.3.17. (S)-1-((2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-
yl)oxy)ethyl)amino)-4-methyl-1-oxopentan-2-yl acetate (20) 
Compound 20 was prepared by following the procedure in previous report.43 Yield 28%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.36 (s, 1H), 7.96 (dd, 1H, J = 6.78, 2.58 
Hz), 7.71 (s, 1H), 7.61 (m, 1H), 7.16 (t, 1H, J = 8.97 Hz), 7.10 (s, 1H), 4.92 (m, 1H), 4.17 
(m, 2H), 3.92 (s, 3H), 3.59 (m, 2H), 2.00 (s, 3H), 1.64 (m, 1H), 1.48 (m, 2H), 0.82 (t, 6H, 




Compound 21 was prepared by following the procedure in previous report.43 Yield 54%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.44 (s, 1H), 8.00 (dd, 1H, J = 6.78, 2.58 
Hz), 7.75 (s, 1H), 7.69-7.66 (m, 1H), 7.26 (t, 1H, J = 6.42 Hz), 7.19 (s, 1H), 4.26 (m, 2H), 
4.00 (s, 3H), 3.99 (m, 2H), 3.69 (m, 1H), 1.75-1.50 (m, 3H), 0.92 (t, 6H, J = 6.21 Hz); 




Compound 22 was prepared by following the procedure in previous report.43 Yield 54%, 
white solid; 1H-NMR (300 MHz, DMSO)  11.05 (s, 1H), 8.81 (s, 1H), 8.20 (s, 1H), 8.03 
(m, 1H), 7.73 (m, 1H), 7.65 (t, 1H, J = 8.79 Hz), 7.31 (s, 1H), 4.24 (m, 2H), 4.00 (s, 3H), 
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Compound 23 was prepared by following the procedure in previous report.43 Yield 55%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.49 (s, 1H), 8.12 (s, 1H), 7.99 (dd, 1H, J = 
6.78, 2.58 Hz), 7.75 (s, 1H), 7.71-7.66 (m, 1H), 7.25 (t, 1H, J = 8.97 Hz), 7.16 (s, 1H), 
4.25 (m, 2H), 3.98 (s, 3H), 3.80 (m, 1H), 3.73 (m, 2H), 1.75-1.58 (m, 3H), 0.90 (dd, 6H, 




Compound 24 was prepared by following the procedure in previous report.43 Yield 57%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.36 (s, 1H), 7.94 (d, J = 6.96 Hz), 7.73 (s, 
1H), 7.60 (m, 1H), 7.15 (t, 1H, J = 8.97 Hz), 7.09 (s, 1H), 4.18 (t, 2H, J = 5.49 Hz), 3.97 
(m, 1H), 3.92 (s, 3H), 3.62 (m, 2H), 1.75 (m, 1H), 1.37-1.45 (m, 2H), 0.82 (dd, 6H, J = 
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Compound 25 was prepared by following the procedure in previous report.32 Yield 46%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.43 (s, 1H), 8.01 (dd, 1H, J = 6.78, 2.58 
Hz), 7.91 (s, 1H), 7.67 (m, 1H), 7.20-7.11 (m, 7H), 4.94 (s, 2H), 4.41-4.37 (m, 4H), 4.08 
(m, 1H), 3.96 (s, 3H), 1.75-1.45 (m, 3H), 0.86 (m, 6H). 
 
4.3.23. (S)-1-(((2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-
yl)oxy)ethoxy)sulfonyl)amino)-4-methyl-1-oxopentan-2-yl acetate (26) 
Compound 26 was prepared by following the procedure in previous report.32 Yield 58%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.41 (s, 1H), 8.04 (dd, 1H, J = 6.78, 2.76 
Hz), 7.92 (s, 1H), 7.76-7.71 (m, 1H), 7.17 (t, 1H, J = 8.97 Hz), 7.10 (s, 1H), 4.83-4.79 




Compound 27 was prepared by following the procedure in previous report.43 Yield 65%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.44 (s, 1H), 8.06 (dd, 1H, J = 6.77, 2.76 
Hz), 7.89 (s, 1H), 7.73 (m, 1H), 7.22 (t, 1H J = 8.97 Hz), 7.14 (s, 1H), 4.48 (m, 4H), 3.98 
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Compound 28 was prepared by following the procedure in previous report.43 Yield 77%, 
white solid; 1H-NMR (300 MHz, CD3OD)  8.43 (s, 1H), 8.06 (dd, 1H, J = 6.78, 2.76 
Hz), 7.90 (s, 1H), 7.70 (m, 1H), 7.20 (t, 1H, J = 9.15 Hz), 7.12 (s, 1H), 4.80 (m, 1H), 4.47 
(m, 4H), 3.98 (s, 3H), 1.80 (m, 1H), 1.55-1.42 (m, 2H), 0.86 (dd, 6H, J = 6.60, 1.65 Hz); 
MS (FAB) m/z 557 (M+H). 
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인간 단백질합성효소 Leucyl-tRNA Sythetase (LRS)를 
표적으로 하는 신규 Mammalian Target of Rapamycin 
Complex 1 (mTORC1) 저해제 개발 
 
Mammalian target of rapamycin (mTOR)은 serine/threonine 단백질 인산화 효소
로서 세포의 대사, 성장, 분열과 자가소화 작용을 조절하는 역할을 한다. 생체 내에
서 mTOR는 mTOR complex 1 (mTORC1)과 mTOR complex 2 (mTORC2)의 두 
개의 구조적으로, 기능성으로 다른 특성을 가진 단백질 복합체로 존재한다. 
Rapamycin에 sensitive하다고 알려진 mTORC1은 세포 내의 아미노산의 농도, 스
트레스 레벨, 세포 증식인자, 에너지 상태 등 세포 안과 밖의 다양한 신호들을 감지
하여 단백질의 합성을 조절한다. mTORC1이 활성화가 되면 세포 신호 전달의 하위 
기질인 S6 kinase 1 (S6K1)과 eukaryotic translation initiation factor 4E 
(elF4E)-binding protein 1 (4E-BP1)을 인산화 시킴으로써 신호 전달이 일어나
고, 이 두 기질은 세포의 성장과 악성종양 형성에 중요한 역할을 한다고 알려져 있
다.  
Rapamycin은 mTORC1의 선택적인 저해제로서 잘 알려져 있으며, FK506-
binding protein 12 (FKBP12)에 결합하여 복합체를 이루어 mTORC1의 
FKBP12-rapamycin binding (FRB) domain에 결합하며, 이와 같은 단백질-단백
질 간 결합을 통해 mTORC1의 효소 촉매 작용을 억제한다. S6K1과 4E-BP1을 
포함하는 신호 전달 과정이 많은 조직에서 악성 종양 형성에 관여하고 있기 때문에 
항암제로서 rapamycin과 그 유도체들에 대한 많은 연구가 진행되고 있다. 
Temsirolimus와 Everolimus는 발전적 콩팥 세포 암에 대한 치료제로 FDA의 승
인을 받은 바 있으며, Ridaforolimus는 발전적 연조직 육종과 골육종에 대하여 최
근 임상 시험 결과 좋은 치료효과를 보이는 것으로 보고되었다. 하지만, rapamycin
과 그 유도체들의 선택적이고 강력한 효능에도 불구하고 여러 암환자를 대상으로 
한 치료에서 일정한 결과를 얻지 못하였다. 그 이유로는 세포 독성을 갖는 억제제
- 117 - 
 
가 아닌 세포 증식 억제제라는 점과 mTORC1의 신호전달을 일부만 저해시킨다는 
제한 점이 있다. 따라서 mTORC1의 활성을 조절할 수 있는 또 다른 조절 인자를 
표적으로 하는 억제제의 개발이 시급한 상황이며, 이는 rapamycin에 저항성을 갖
는 암세포에 대하여 효과적인 새로운 항암 치료 전략이 될 수 있을 것이라 기대하
였다.  
mTORC1의 활성에 영향을 미치는 다양한 환경적 요인들 중, 단백질의 합성에 관
여하는 필수 아미노산 중 류신이 아미노산에 의한 mTORC1의 활성화에 주된 조절 
인자로 작용한다고 알려져 있다. 류신이 mTORC1을 활성화시키는 기전에 대하여 
완벽히 규명되지는 않았지만, 최근 여러 연구 결과에 따르면 leucyl-tRNA 
synthetase (LRS)가 세포 안의 아미노산에 의해 mTORC1이 활성화되는 신호 전
달 과정에 주요 인자인 RagD GTPase와 직접적으로 결합하여 류신의 센서로서 작
용한다고 보고되었다. LRS는 세포 안에서 단백질 합성 효소로서 ATP 의존적으로 
류신을 그 cognate transfer RNA (tRNA)에 연결시켜주는 반응을 촉매 한다. 또한, 
LRS에 류신이 결합하게 되면 RagD GTPase에 대하여 GTPase-activating 
protein (GAP)의 역할을 하는 것으로 보고 되었으며, RagD-GTP의 가수분해를 촉
진하여 mTORC1을 활성화 시킨다. 또한, 류신에 의해 활성화된 mTORC1은 그 유
도체인 류시놀에 의해 억제될 수 있다고 보고 된 바 있으며, 이 과정에서 LRS의 
tRNA에 류신을 charging하는 활성에는 영향을 미치지 않는 것으로 보고 되었다. 
선행 연구를 기반으로 하여 본 연구실에서는 첫 번째로, leucine의 유도체인 
leucinol의 유도체들을 합성하여 LRS를 통해 활성화된 mTORC1을 저해하는지 여
부를 확인하였고, 그 결과 mTORC1에 대하여 가장 강력한 활성을 보인 (S)-
Isobutyloxazolidin-2-one의 화합물을 도출하였다. 이 화합물은 rapamycin에 저
항성을 갖는 SW620 세포에 대하여 농도 의존적인 세포독성을 갖는 것을 확인하였
다. 
이후 LRS의 저해제로서 잘 알려진 leucyladenylate sulfamate 구조를 기반으로 하
여 LRS를 표적으로 하는 mTORC1 저해제를 디자인하였다. 기존 저분자 유도체들
보다 추가적인 binding interaction을 통해 좀 더 강력한 mTORC1 저해제 개발을 
할 수 있을 것이라 기대하였다. 연구 결과, leucyladenylate sulfamate 구조에서 
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leucine의 a위치에 amino 그룹을 hydroxyl 그룹으로 치환하고, adenine의 2번 위
치를 iodine으로 치환한 화합물이 농도 의존적으로 mTORC1을 억제하며, 
mTORC1이 과발현 되어있는 대장암 세포 (HCT116) 에서 선택적인 세포독성을 
갖는 것을 확인하였다.  
다음으로 이러한 유도체들이 화학적으로 극성이 높아 대량 합성상의 어려움이 있고, 
낮은 생체 이용률로 인한 전임상 단계 진입의 어려움을 극복하고자 구조를 단순화
하여 물리화학적 특성을 개선한 유도체들을 디자인하였다. 구조적으로 5-O-
sulfamoylribose를 simplify하여 benzene sulfonamide 그룹으로 치환하였다. 본 
연구실에서 보유하고 있는 화합물 라이브러리 중 adenine의 구조를 3,4-
dimethoxyphenyl 또는 2-phenoxy 구조로 치환하여 화합물을 디자인하였고, side 
chain에는 선행 연구에서 좋은 결과를 보였던 rigid한 구조를 도입하여 구조 활성 
연구를 진행하였다. 연구 결과, 5-O-sulfamoylribose를 benzenesulfonamide로 
치환하고 adenine을 3,4-dimethoxyphenyl 그룹으로 치환한 유도체가 좋은 활성
을 보였으며, 이들 화합물 중 선도 화합물 대비 3배 이상 더 강력한 활성을 보이는 
화합물을 도출할 수 있었다. 또한, 이 화합물 역시 여섯 가지의 암세포에 대하여 전
반적인 세포독성을 확인하였고 이러한 연구 결과로 LRS를 표적으로 하여 
mTORC1의 활성을 저해하는 항암제 개발의 가능성을 확인하였다.  
또한, 본 연구실의 simplified leucyladenylate 유도체 라이브러리 중, gefitinib 구
조를 도입하여 새로운 scaffold를 갖는 화합물을 디자인하여 구조 활성 연구를 수
행하였다. Adenine 구조를 N-(3-chloro-4-fluorophenyl)quinazolin-4-amine
로 치환하였고, 5-O-sulfamoylribose 구조 대신에 다양한 linker를 갖는 화합물을 
디자인하여 최적의 LRS을 표적으로 하는 mTORC1 저해제를 도출하고자 하였다. 
연구 결과, leucyl side chain과 adenylate binding site 사이에 sulfonamide, ethyl 
alcohol 또는 ethyl amino linker를 포함하는 화합물에서 강력한 저해 활성을 확인
하였다. linker의 길이가 너무 짧거나 긴 경우 LRS의 binding site에 화합물이 결합
하지 못해 활성이 현저하게 감소하는 것을 확인할 수 있었으며, 이 화합물들 모두 
여섯 가지의 암세포에 대하여 전반적인 세포독성을 확인할 수 있었다.  
주 요 어: Leucyl-tRNA Synthetase, mTORC1 Inhibitor, Leucinol, Anticancer Agent 
